UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: ~~September 30~~March 31, ~~2016~~2017

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ___________

Commission File Number: 001-28911

CANNABIS SCIENCE, INC.

(Exact name of registrant as specified in its charter)

Nevada	91-1869677
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
19800 MacArthur Blvd., Suite 300, Irvine, California	92612
(Address of principal executive offices)	(Zip Code)
(888)263-0832
(888) 263-0832
(Registrant’ s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a not-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ] ~~Non-accelerated filer [ ] Smaller reporting company [X]~~

Non-accelerated filer [ ] Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). [ ] Yes [X] No

Number of common shares issued and outstanding at ~~September~~March 3031, ~~2016~~2017: 2,~~327~~443,~~855~~355,296

Number of common shares outstanding at July ~~November 7~~14, ~~2016~~2017: 2,~~312~~466,~~305~~805,296

Number of Class A common shares outstanding at ~~October~~July 3114, ~~2016~~2017: 0

CANNABIS SCIENCE, INC.

FORM 10-Q

For the Period Ended ~~September~~March 3031, ~~2016~~2017

TABLE OF CONTENTS

Page PART I FINANCIAL INFORMATION 2 Item 1. Consolidated Financial Statements 2 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 3 Item 3. Quantitative and Qualitative Disclosures about Market Risk 8 Item 4. Controls and Procedures 8 PART II OTHER INFORMATION 9 Item 1. Legal Proceedings 9 Item 1A. Risk Factors 9 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 9 Item 3. Defaults Upon Senior Securities 12 Item 4. Mine Safety Disclosures. 12 Item 5. Other Information 12 Item 6. Exhibits and Certifications 12


	Page
PART I FINANCIAL INFORMATION		3
Item 1. Consolidated Financial Statements		3
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations		4
Item 3. Quantitative and Qualitative Disclosures about Market Risk		10
Item 4. Controls and Procedures		11
PART II OTHER INFORMATION		11
Item 1. The Business		11
Item 1A. Risk Factors		12
Item 2 Legal Proceedings		13
Item 3. Unregistered Sales of Equity Securities and Use of Proceeds		14
Item 4. Defaults Upon Senior Securities		14
Item 5. Mine Safety Disclosures.		14
Item 6. Other Information		14
Item 7. Exhibits and Certifications		15

PART I FINANCIAL INFORMATION.

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

CANNABIS SCIENCE, INC.

	Page No.
Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015	F-1
Consolidated Statements of Operations and Other Comprehensive Income (Loss) for three and nine months ended September 30, 2016 and 2015	F-2
Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015	F-3
Consolidated Statements of Stockholders’ Deficit for the nine months ended September 30, 2016	F-4
Notes to Consolidated Financial Statements	F-5

CANNABIS SCIENCE, INC. CONSOLIDATED BALANCE SHEETS September 30, 2016 and December 31, 2015
	September 30, 2016			December 31, 2015
	(UNAUDITED)
	$			$
ASSETS
Current Assets
Cash		11,045			61,971
Other receivables		35,193			39,366
Loans receivable, related party		20,000			37,516
Inventory		93,050			19,311
Prepaid expenses and deposits		235,744			156,750
Total current assets		395,032			314,914
Property farming license (Note 7)		48,611			—
Deposits (Note 8)		181,350			971,500
Equity method investee (Note 9)		129,248			128,927
Goodwill (Note 10)		145,086			170,689
Intangibles, net of accumulated amortization (Note 10)		182,750			215,000
TOTAL ASSETS		1,082,077			1,801,030
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable		1,091,831			680,215
Accrued expenses, primarily management fees (Note 4)		1,451,465			1,614,654
Advances from related parties (Note 4)		517,861			414,135
Management bonuses		300,000			300,000
Notes payable to stockholders (Note 5)		2,065,563			1,406,513
Total current liabilities and total liabilities		5,426,720			4,415,517
Stockholders’ Deficit
Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at
September 30, 2016 and December 31, 2015		1,000			1,000
Common stock, $.001 par value, 3,000,000,000 shares authorized,
2,327,855,296 issued and outstanding as of September 30,2016 and
1,581,855,296 at December 31, 2015		2,327,856			1,581,856
Common stock, Class A, $.001 par value, 100,000,000 shares
authorized, 0 issued and outstanding as of September 30, 2016 and December 31, 2015		—			—
Prepaid consulting		(1,199,890	)		(3,209,032	)
Common Stock receivable		(2,499,000	)		(381,500	)
Additional paid-in capital, including 110,850,000 shares pending to be issued and 300,000 shares voided		137,607,273			127,942,191
Accumulated deficit		(139,971,991	)		(128,017,132	)
Cumulative exchange translation		(18,104	)		(18,496	)
Equity attributable to common shareholders		(3,752,856	)		(2,101,113	)
Non-Controlling interest		(591,787	)		(513,374	)
Total stockholders' deficit		(4,344,643	)		(2,614,487	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		1,082,077			1,801,030

PART I FINANCIAL INFORMATION.

~~The accompanying~~ITEM ~~notes~~1. ~~are~~CONSOLIDATED anFINANCIAL ~~integral part of these consolidated financial statements.~~ STATEMENTS

~~F-1~~CANNABIS SCIENCE, INC.

CANNABIS SCIENCE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME(LOSS) FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2016 and 2015

		Page No.

Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016…		F-1

Consolidated Statements of Operations and Other Comprehensive Income (Loss) for the three months ended March 31, 2017 and 2016…		F-2

Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016…		F-3

Consolidated Statements of Stockholders’ Deficit for the three months ended March 31, 2017		F-4

Notes to Consolidated Financial Statements…		F-5

~~(UNAUDITED)~~3

	For the three months						For the nine months
CANNABIS SCIENCE, INC.
	ended September 30,						ended September 30,
CONSOLIDATED BALANCE SHEETS
	2016			2015			2016			2015
March 31, 2017 and December 31, 2016
	$			$			$			$
	March 31, 2017			December 31, 2016
REVENUE		2,733			4,150			8,520			4,150
	(UNAUDITED)
Cost of Goods Sold		1,407			2,088			3,609			2,088
	$			$
Gross Profit		1,326			2,062			4,911			2,062
ASSETS
Operating Expenses
Current Assets
Investor relations		48,950			(10,500	)		267,300			—
Cash		316,591			332,888
Professional Fees		58,962			22,424			254,079			626,132
Other receivables		15,520			36,001
Net loss on settlement of liabilities		3,550,000			770,000			4,138,645			4,488,076
Prepaid expenses and deposits held with RMS (Note 11)		275,744			808,514
Loss on investment		971,500			—			971,500			—
Inventory		103,868			102,993
Depreciation and Amortization		19,284			—			57,853			—
Total current assets		711,723			1,280,396
Research and Development		6,487			68,552			265,024			381,772
Equipment and Greenhouse, net (Note 7)		330,729			—
General and administrative		2,301,712			2,967,024			6,082,880			8,710,982
Property Farming Rights (Note 8)		804,492			751,726
Total operating expenses		6,956,895			3,817,500			12,037,281			14,206,962
Equity method investee (Note 9)		325,277			272,644
Net Operating (Loss)		(6,955,569	)		(3,815,438	)		(12,032,370	)		(14,204,900	)
Intangibles, net of accumulated amortization (Note 10)		161,250			172,000
Other (expense)
TOTAL ASSETS		2,333,471			2,476,766
Interest expense, net		—			(603	)		(902	)		(603	)
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Impairment of goodwill		—			—						(64,421	)
Current Liabilities
Unrealized gain (loss) on marketable common stock		—			(79,500	)					(87,000	)
Accounts payable		839,903			856,269
Total other income (expense)		—			(80,103	)		(902	)		(152,024	)
Accrued expenses, primarily management fees (Note 4)		1,062,336			884,465
Net Loss		(6,955,569	)		(3,895,541	)		(12,033,272	)		(14,356,924	)
Advances from related parties (Note 4)		572,785			538,425
Less: Net loss attributable to non-controlling interest		—			177,621			78,413			232,589
Management bonuses		300,000			300,000
Net loss attributable to common shareholders		(6,955,569	)		(3,717,920	)		(11,954,859	)		(14,124,335	)
Notes payable to stockholders (Note 5)		1,590,715			1,506,745
Other Comprehensive Income (Loss)
Notes payable (Note 5)		396,303			177,698
Foreign exchange translation adjustment		(201	)		(49,708	)		392			(79,249	)
Total current liabilities and total liabilities		4,762,042			4,263,602
Total other comprehensive income (Loss)		(201	)		(49,708	)		392			(79,249	)
Stockholders’ Deficit
Comprehensive loss attributable to Cannabis Science, Inc.		(6,955,770	)		(3,767,628	)		(11,954,467	)		(14,203,584	)
Series A Preferred stock, $0.001 par value, 1,000,000 shares
Net loss per common share:
authorized, 1,000,000 shares issued and outstanding at
Basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.01	)
March 31, 2017 and December 31, 2016		1,000			1,000
Weighted average number of common shares outstanding		2,106,170,513			1,285,416,166			1,894,510,405			1,213,795,570
Common stock, $.001 par value, 3,000,000,000 shares authorized,
The accompanying notes are an integral part of these consolidated financial statements.
2,443,355,296 issued and outstanding as of March 31,2017 and
2,350,355,296 at December 31, 2016		2,443,356			2,350,356
Common stock, Class A, $.001 par value, 100,000,000 shares
authorized, 0 issued and outstanding as of March 31, 2017 and December 31, 2016		—			—
Prepaid consulting		(3,759,810	)		(1,705,659	)
Common Stock receivable		(2,680,000	)		(655,000	)
Additional paid-in capital		144,292,020			136,963,520
Accumulated deficit		(142,163,656	)		(138,137,771	)
Cumulative exchange translation		(15,980	)		(11,495	)
Equity attributable to common shareholders		(1,883,070	)		(1,195,049	)
Non-Controlling interest		(545,501	)		(591,787	)
Total stockholders' deficit		(2,428,571	)		(1,786,836	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		2,333,471			2,476,766

~~F-2~~ The accompanying notes are an integral part of these consolidated financial statements.

~~CANNABIS SCIENCE, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2016 and 2015 (UNAUDITED)~~F-1

	September 30, 2016			September 30, 2015
	$			$
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		(12,033,272	)		(14,356,924	)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization		57,853			—
Stock issued for services		3,825,874			8,585,654
Stock options issued for services		1,138,500			—
Loss on investment		971,500			—
(Gain) / Loss on settlement of liability		4,138,645			4,488,076
(Gain) / Loss on Equity Investee, Omnicanna Health Solutions, Inc.		—			87,788
Foreign exchange translation adjustment		392			(79,249	)
Changes in operating assets and liabilities: Accounts receivables		4,173			5,883
Equity investee		(321	)		—
Inventory		(73,739	)		1,937
Prepaid expenses and deposits		11,250			9,038
Accounts payable		411,616			570,893
Accrued expenses, primarily management fees		812,218			313,000
NET CASH USED IN OPERATING ACTIVITIES		(735,310	)		(373,904	)
CASH FLOWS FROM INVESTING ACTIVITIES
Advances receivable, related parties		17,516			33,615
Repayment of advances receivable, related parties		—			(7,351	)
Cash acquired with Equi-Pharm		—			6,493
Prepaid Expenses		(244	)		—
Property license for cultivation		(48,611	)		—
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES		(31,339	)		32,757
CASH FLOWS FROM FINANCING ACTIVITIES
Loan receivable, related parties		82,369			—
Proceeds from notes payable to stockholders		295,855			85,877
Repayment of notes payable to stockholders		(295,000	)		—
Proceeds from common stock options exercised		632,500			—
Proceeds from sale of common stock		—			250,000
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		715,724			335,877
NET (DECREASE) IN CASH		(50,926	)		(5,270	)
CASH, BEGINNING OF PERIOD		61,971			10,061
CASH, END OF PERIOD		11,045			4,791
SUPPLEMENTAL CASH FLOW INFORMATION:
Common stock issued for services		1,816,732			10,228,944
Common stock issued for settlement of debt		4,434,500			4,733,904
Common stock issued for options exercised		3,888.500			—
Common stock subscription receivables		2,499,000			615,000
Common stock issued for assets		271,350			—
Common stock issued for acquisition of EquiPharm		—			305,000
Debt converted into common stock		295,000			245,828
Related Party Receivable - RCDU		20,000			—
Accounts payable paid through note payable, stockholder		—			130,854
Accounts payable and expenses paid through advances from related parties		29,852			466,106
Stocks Dividends Payable		—			473,527

CANNABIS SCIENCE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS)

FOR THE THREE MONTHS ENDED MARCH 31, 2017 and 2016

~~The accompanying notes are an integral part of these consolidated financial statements.~~ (UNAUDITED)

F-3


	For the three months
	ended March 31,
	2017			2016
	$			$
REVENUE		3,733			2,925
Cost of Goods Sold		1,921			1,598
Gross Profit		1,812			1,327
Operating Expenses
Investor relations		20,700			157,000
Professional Fees		82,374			81,690
Net loss on settlement of liabilities		—			588,645
Depreciation and Amortization		10,814			19,285
Research and Development		216,943			163,000
General and administrative		3,400,505			2,391,689
Total operating expenses		3,731,336			3,401,309
Net Operating Loss		(3,729,524	)		(3,399,982	)

Other income (expense)
Interest expense, net		(302,575	)		(35	)
Unrealized gain on equity investee		52,500			69,000
Total other income (expense)		(250,075	)		68,965
Net Loss		(3,979,599	)		(3,331,017	)
Net (Income) loss attributable to non-controlling interest		(46,286	)		40,045
Net loss attributable to common shareholders		(4,025,885	)		(3,290,972	)
Other Comprehensive Income (Loss)
Foreign exchange translation adjustment		(4,485	)		(2,096	)
Total other comprehensive income (Loss)		(4,485	)		(2,096	)
Comprehensive loss attributable to Cannabis Science, Inc.		(4,030,370	)		(3,293,068	)

Net loss per common share:
Basic and diluted	$	(0.00	)	$	(0.00	)

Weighted average number of common shares outstanding		2,389,710,852			1,680,393,758

The accompanying notes are an integral part of these consolidated financial statements.

~~CANNABIS SCIENCE, INC.~~F-2

CANNABIS SCIENCE, INC. CONSOLIDATED ~~STATEMENT~~ STATEMENTS OF ~~STOCKHOLDERS’~~CASH ~~DEFICIT~~FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2017 and 2016 (UNAUDITED)

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2016

	March 31, 2017			March 31, 2016
	$			$
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		(3,979,599	)		(3,331,017	)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization		21,797			19,285
Interest on debt conversion		302,575			—
Stock issued for services		2,712,349			1,738,220
Stock options issued for services		630,000			437,000
(Gain) / Loss on settlement of liability		—			588,645
(Gain) / Loss on Equity Investee, Omnicanna Health Solutions, Inc.		(52,500	)		(69,000	)
Changes in operating assets and liabilities: Other receivables		20,481			(16,948	)
Prepaid expenses and deposits held with RMS		529,020			(6,088	)
Equity investee		(133	)		(435	)
Inventory		(875	)		(64,956	)
Property farming rights		(60,000	)		—
Accounts payable		(16,366	)		67,166
Accrued expenses, primarily management fees		177,871			319,000
Loan receivable, related parties		34,360			22,945
NET CASH USED IN OPERATING ACTIVITIES		318,980			(296,183	)
CASH FLOWS FROM INVESTING ACTIVITIES
Equipment and Greenhouse		(766	)		—
Greenhouse		(330,026	)		—
Property farming rights		—			(25,000	)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES		(330,792	)		(25,000	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from common stock options exercised		—			276,500
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		—			276,500

Effect on exchange rate changes on cash		(4,485	)		(2,096	)
NET DECREASE IN CASH		(16,297	)		(46,779	)
CASH, BEGINNING OF PERIOD		332,888			61,971
CASH, END OF PERIOD		316,591			15,192

SUPPLEMENTAL CASH FLOW INFORMATION:
Common stock issued for services		—			1,170,982
Common stock issued for settlement of debt		—			634,500
Common stock issued for options exercised		—			1,338,050
Debt converted into common stock		—			45,855

~~(UNAUDITED)~~The accompanying notes are an integral part of these consolidated financial statements.

	Common Shares		Par		Preferred Shares		Par		Additional Paid-In Capital		Prepaid Consulting			Common Stock Receivable		Accumulated Deficit			Foreign Exchange Translation		Non-Controlling Interest			Totals
			$				$		$		$			$		$			$		$			$
Balance at December 31, 2015		1,581,855,296		1,581,856		1,000,000		1,000		127,942,191		(3,209,032	)	(381,500	)		(128,017,132	)	(18,496	)		(513,374	)		(2,614,487	)
Common stock issued for services		153,000,000		153,000						1,663,732		(741,364	)	—											1,075,368
Common stock issued for settlement of liabilities and debt		295,000,000		295,000						4,139,500				—											4,434,500
Common stock issued for private placement		—		—						—				—											—
Common stock issued for deposit to acquire assets		23,000,000		23,000						248,350				—											271,350
Common stock issued for stock option exercised		275,000,000		275,000						3,613,500				(2,117,500	)										1,771,000
Amortization of shares issued for services												2,750,506													2,750,506
Net loss for the period																	(11,954,859	)				(78,413	)		(12,033,272	)
Foreign exchange translation																			392						392
Balance at September 30, 2016		2,327,855,296		2,327,856		1,000,000		1,000		137,607,273		(1,199,890	)	(2,499,000	)		(139,971,991	)	(18,104	)		(591,787	)		(4,344,643	)

F-3

~~The accompanying~~CANNABIS ~~notes~~SCIENCE, ~~are an integral part of these consolidated financial statements~~INC.

~~F-4~~CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY/(DEFICIT)

~~CANNABIS SCIENCE,~~FOR ~~INC.~~THE THREE MONTHS ENDED March 31, 2017

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

	Common Shares		Par		Preferred Shares		Par		Additional Paid-In Capital		Prepaid Consulting			Accumulated Deficit			Common Stock Receivable			Cumulative Exchange Translation			Equity Attributable to Common Shareholders			Non-Controlling Interest			Totals
			$				$		$		$			$			$			$			$			$			$
Balance at December 31, 2016		2,350,355,296		2,350,356		1,000,000		1,000		136,963,520		(1,705,659	)		(138,137,771	)		(655,000	)		(11,495	)		(1,195,049	)		(591,787	)		(1,786,836	)
Common stock issued for services		58,000,000		58,000						4,708,500		(2,559,000	)					—						2,207,500						2,207,500
Common stock issued for stock option exercised		35,000,000		35,000						2,620,000								(2,025,000	)					630,000						630,000
Amortization of shares issued for services												504,849												504,849						504,849
Net loss for the period															(4,025,885	)								(4,025,885	)		46,286			(3,979,599	)
Foreign exchange translation																					(4,485	)		(4,485	)					(4,485	)
Balance at March 31, 2017		2,443,355,296		2,443,356		1,000,000		1,000		144,292,020		(3,759,810	)		(142,163,656	)		(2,680,000	)		(15,980	)		(1,883,070	)		(545,501	)		(2,428,571	)

~~September~~The accompanying notes are ~~30,~~an ~~2016~~integral part of these consolidated financial statements.

~~(UNAUDITED)~~F-4

~~1. SUMMARY~~CANNABIS OFSCIENCE, ~~SIGNIFICANT ACCOUNTING POLICIES~~INC.

~~A. Organization~~NOTES ~~and~~TO ~~General~~CONSOLIDATED ~~Description~~FINANCIAL ~~of Business~~STATEMENTS

Cannabis Science, Inc. (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 2531, ~~2008 the Company changed its name to Gulf Onshore, Inc. On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.~~ 2017

~~On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTCBB: CBIS.~~(UNAUDITED)

~~Cannabis Science, Inc~~1. ~~is at the forefront of medical marijuana research and development.~~ ~~The~~SUMMARY ~~Company~~OF ~~works~~SIGNIFICANT ~~with~~ACCOUNTING world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10th and May 6th, 2013, respectively, to pursue business opportunities in Europe and worldwide. There are currently minimal operations in the subsidiaries. Agreements and business disclosures are in process.POLICIES

~~On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders~~A.~~" The~~ ~~subject~~Organization ofand ~~the~~General ~~patent~~Description ~~is development~~ of ~~cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.~~ Business

~~On November~~Cannabis 20Science, ~~2014,~~Inc. (“We” ~~the~~or “the Company”), ~~signed~~was anincorporated ~~amendment~~under to the ~~license~~laws ~~agreement~~of ~~with~~the ~~Apothecary~~State ~~Genetics~~of ~~Investments LLC. Pursuant to the amendment~~Colorado, ~~the~~on ~~Company~~February ~~was to acquire all property~~29, ~~building~~1996, ~~and~~as ~~equipment~~Patriot ofHoldings, ~~Apothecary~~Inc. ~~The Company signed a second~~ On ~~amendment~~August on26, ~~January 11~~1999, ~~2016~~the ~~which~~Company ~~superseded~~changed ~~both~~its ~~License~~name ~~Agreement~~to ~~and~~National ~~November~~Healthcare 20Technology, ~~2014~~Inc. ~~Amendment~~On byJune ~~the~~6, ~~issuance of additional 15~~2007,~~500,000~~ ~~shares~~the ofCompany ~~Rule~~changed ~~144~~its name ~~restricted~~from ~~common~~National ~~stock~~Healthcare ~~for~~Technology, ~~a property located in Northern California~~Inc. ~~The 14~~,~~500,000~~ ~~shares~~to ~~of Rule~~Brighton ~~144~~Oil ~~restrict~~& ~~common stock~~Gas, ~~valued at $971~~Inc.,~~500~~ ~~as deposit, issued in November of 2014 were for compensation of research~~ and ~~development~~ onconverted ~~the~~to ~~Northern~~a ~~California~~Nevada ~~property~~corporation. On March ~~The~~25, ~~Company~~2008 ~~wrote off~~ the ~~deposit~~Company aschanged ~~Research~~its ~~and~~name ~~Development~~to ~~expenses~~Gulf ~~for the period ended September 30~~Onshore, ~~2016~~Inc. On InApril ~~the month of July 2016~~6, ~~Apothecary Genetics Investments~~2009, ~~LLC breached~~ the ~~amended~~Company ~~agreement by~~changed ~~refusing~~its toname ~~transfer the Northern California property~~ to ~~the Company and demanded additional paymentfor the property. The Company~~Cannabis ~~declined~~Science, ~~to pay additional funds for the property and put the project on hold~~Inc.~~All the 15~~,~~500,000~~ ~~Rule~~and ~~144~~obtained ~~restricted~~a ~~common~~new ~~shares are~~CUSIP ~~held in escrow until further decision by the management of the Company~~number.

B. On May 7, 2009 the Company common shares commenced trading ~~Basis~~under ofthe ~~Presentation~~new stock symbol OTC Pink: CBIS.

~~These~~Cannabis Science, Inc. is at the forefront of medical marijuana ~~consolidated~~research ~~financial~~and ~~statements~~development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and ~~related~~adheres ~~notes~~to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are ~~presented~~dedicated into ~~accordance~~the creation of cannabis-based medicines, both with ~~accounting~~and ~~principles~~without ~~generally~~psychoactive ~~accepted~~properties, to treat indisease and the ~~United~~symptoms ~~States~~of disease, as well as for general health maintenance. The Company formed two operating subsidiaries Cannabis Science BV and ~~are~~Cannabis ~~expressed~~Science International Holding BV in ~~U.S.~~The ~~dollars~~Netherlands on May 10 th and May 6 th, 2013, respectively, to pursue business opportunities in Europe and worldwide. ~~The~~There ~~Company’s~~are ~~fiscal~~currently ~~year~~minimal ~~end~~operations isin ~~December~~the subsidiaries. Agreements 31and business disclosures are in process.

FOn November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-5based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.

~~Interim Financial~~B. Basis ~~Reporting~~of Presentation

~~While the~~These ~~information presented in the accompanying interim~~ consolidated financial statements isand ~~unaudited,~~related ~~it includes all adjustments,~~notes ~~which~~ are ~~in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods~~ presented in accordance with ~~general accepted~~ accounting principles generally accepted in the United States, ~~of America (“GAAP”). These interim financial statements follow the same accounting policies~~ and ~~methods~~are ofexpressed ~~application as used~~ in ~~the December 31, 2015 audited financial statements of Cannabis Science, Inc~~U. ~~(the “Company”)~~S. ~~All adjustments are of a normal, recurring nature~~dollars. ~~Interim financial statements and the notes thereto do not contain all of the disclosures normally found in the year-end~~ ~~audited~~ The financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the nine month periods ended September 30, 2016 and 2015. It is suggested that these interim financial statements be read in conjunction with the Company’s ~~audited~~fiscal ~~financial statements and related notes for the~~ year ~~ended~~end ~~December~~is 31, 2015 included in our Form 10-K filed with the SEC on file no. 000-28911 161631274 May 9, 2016. Operating results for the nine months ended September 30, 2016 are not necessarily indicative of the results that can be expected for the year ending December 31~~, 2016~~.

~~The following~~Interim ~~subsidiaries~~Financial ~~and controlling interests are included with the consolidated financial statements of the Company for the nine months ended September 30, 2016:~~Reporting

InWhile the information presented in the accompanying ~~2012~~interim consolidated financial statements is unaudited, ~~the~~it ~~Company~~includes ~~formed~~all ~~Cannabis~~adjustments, ~~Science~~which ~~Europe~~are ~~GmbH~~in ~~(“CSE”)~~the opinion of management, necessary to ~~operate~~present ~~joint-venture~~fairly the financial position, results of operations ~~with~~and ~~Dupetit~~cash ~~Natural~~flows for the interim periods presented in accordance ~~Products~~with ~~Ltd. The~~general JVaccepted ~~asset~~accounting ~~was~~principles ~~sold~~in tothe ~~Endocan~~United ~~Corporation~~States ~~(formerly~~of ~~X-Change~~America ~~Corporation~~(“GAAP”). onThese ~~December~~interim ~~12,~~financial ~~2012. No~~statements ~~operations~~follow ~~had~~the ~~commenced~~same ataccounting ~~the~~policies ~~time~~and methods of ~~sale~~application ofas used in the JVDecember ~~asset.~~31, ~~The~~2016 ~~Company~~audited ~~has~~financial ~~reignited~~statements ~~the~~of Cannabis ~~CSE~~Science, byInc. ~~appointing~~(the Mr“Company”). ~~Alfredo~~All ~~Dupetit on~~adjustments ~~September~~are 19of a normal, ~~2015~~recurring asnature. ~~president~~Interim financial statements and ~~chief~~the ~~executive~~notes ~~officer~~thereto ofdo ~~CSE.~~not Ascontain ~~recent~~all asof ~~January~~the 7,disclosures ~~2016,~~normally found in the ~~Federal~~year-end ~~Health~~audited ~~Ministry in~~financial ~~Germany~~statements ~~has~~and ~~presented~~these Notes ~~“Cannabis~~to asFinancial ~~medicine”,~~Statements aare ~~detailed~~abbreviated ~~draft~~and ~~bill~~contain ~~that~~only ~~aims~~certain todisclosures ~~modify~~related to the ~~Drug~~three-month ~~Law~~periods ~~and~~ended ~~relax~~March ~~the~~31, ~~strict~~2017 ~~measures~~and ~~that~~2016. ~~regulate~~It ~~the~~is ~~consumption~~suggested ofthat ~~medical~~these ~~cannabis~~interim ~~and,~~financial ~~above~~statements ~~all,~~be ~~become~~read ~~the~~in ~~main~~conjunction ~~vehicle~~with ~~for~~the ~~everything~~Company’s ~~relating~~audited tofinancial statements and related notes for the ~~plant~~year ~~and~~ended ~~its~~December ~~medical~~31, ~~users~~2016 included in our Form 10-K filed with the ~~country~~SEC on file no. ~~The~~ ~~Company~~000-28911 ~~has~~161631274 ~~reinstated~~April 17, 2017. Operating results for the ~~development~~three ofmonths ~~cannabis~~ended ~~products~~March in31, ~~February~~2017 are not necessarily indicative ~~2016~~of the results that can be expected for ~~medicinal~~the ~~uses~~year inending ~~Germany~~December 31, 2017.

~~On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly~~F-owned operating subsidiaries for the Company’s European and world-wide operations. The Company has commenced some operating activities with cultivation in Spain and product development in 2014. Mario Lap, director of the Company and director and officer of Cannabis Science B.V. manages the day-to-day operations through his private companies MLS BV, MJR BV and Cannabis Agency BV, all are Netherlands registered companies.5

~~On August~~The 6,following ~~2014,~~subsidiaries ~~the~~and ~~Company~~controlling ~~signed~~interests are aincluded ~~proposal letter~~ with ~~Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT and completed~~ the ~~transaction~~consolidated ~~with~~financial ~~the~~statements ~~principals~~ of ~~MGT under~~ the ~~proposal letter on February 20, 2015 to effectively increase the~~ Company’s ~~equity ownership to 50.1%. As consideration~~ for ~~acquiring~~ the ~~additional~~three ~~30.1% equity,~~months ~~the~~ended ~~Company~~March ~~issued 1~~31,~~200,000~~ ~~shares of common stock with a fair market value of $60,000 to the principals and shareholders of MGT.~~2017:

~~On May~~In 62012, ~~2015~~ the Company ~~announced~~formed ~~the~~Cannabis Science ~~Assets~~Europe ~~acquisition~~GmbH of(“CSE”) ~~Equi-Pharm~~in ~~LLC,~~which athe ~~USA~~Company ~~manufacturer~~own ~~and~~90% ~~distributor~~to ofoperate ~~specialty~~joint-venture ~~horse and~~operations ~~pet~~with ~~grooming~~Dupetit ~~and~~Natural ~~topical applications~~Products Ltd. The ~~acquisition~~JV ~~incorporates~~asset anwas ~~extensive~~sold ~~expansion~~to ~~plan~~Endocan ~~for~~Corporation ~~Equi~~(formerly X-~~Pharm~~Change ~~including~~Corporation) ~~"Large Animal"~~on ~~such~~December ~~as horses~~12, ~~cattle,~~2012. No ~~sheep~~operations had ~~and~~commenced at the ~~like~~time ~~and~~of ~~"Small~~sale ~~Animal"~~of orthe ~~"Pets"~~JV ~~include~~asset. ~~cats,~~The ~~dogs,~~Company ~~pet snakes~~has ~~and~~reignited the ~~like~~CSE ~~for~~by ~~medical~~appointing ~~and~~Mr. ~~cosmetic~~Alfredo ~~products.~~Dupetit Ason ~~consideration~~September 19, ~~for~~2015 ~~acquiring~~as ~~the~~president ~~Assets,~~and ~~which~~chief ~~consist~~executive officer of ~~Inventory, Trademark~~CSE. ~~and~~As ~~brand~~recent ~~names,~~as ~~and~~January ~~goodwill~~7, 2016, the ~~Company~~Federal ~~issued~~Health ~~ten~~Ministry ~~million~~in ~~(10~~Germany has presented “Cannabis as medicine”,~~000,000)~~ ~~shares~~a detailed draft bill that aims to modify the ~~shareholders~~Drug ofLaw ~~Equi-Pharm~~ and ~~they~~relax ~~agreed~~the tostrict ~~change~~measures that ~~its~~regulate ~~company~~the ~~name.~~consumption ~~The~~of ~~acquisition~~medical ~~was~~cannabis ~~completed~~and, onabove ~~November 16~~all, ~~2015~~become ~~and~~ the ~~Company~~main ~~has~~vehicle ~~formed~~for aeverything ~~new wholly~~relating ~~owned~~to ~~subsidiary~~the ~~called~~plant and ~~Equi-Pharm~~its ~~LLC.~~medical users in the ~~state~~country. The ofCompany ~~Tennessee~~has ~~and~~reinstated ~~started~~ the ~~operation~~development of ~~distributing~~cannabis ofproducts ~~existing and~~in ~~new~~February ~~line~~2016 offor medicinal ~~products~~uses in Germany.

~~For~~On May 6, 2013, the Company formed ~~other~~Cannabis ~~accounting~~Science ~~policies~~International ~~please~~Holdings ~~refer~~B.V. toand on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s ~~Form~~European 10and world-Kwide operations. The Company has commenced some operating activities with cultivation in Spain and product development in 2014. Mario Lap, director of the ~~SEC~~Company onand ~~file~~director noand officer of Cannabis Science B.V. ~~000~~manages the day-~~28911~~to-day ~~161631274~~operations ~~May~~through 9his private companies MLS BV, ~~2016~~MJR BV and Cannabis Agency BV, all are Netherlands registered companies.

~~The Company~~On ~~qualifies~~August as6, an2014, ~~“emerging~~the ~~growth~~Company ~~company”~~signed asa ~~defined~~proposal inletter ~~Section~~with Michigan ~~101~~Green ofTechnologies, ~~the~~LLC ~~Jumpstart our Business Startups Act~~ (“~~JOBS Act~~MGT”) asto weacquire doan ~~not~~additional ~~have~~30.1% ~~more~~equity ~~than~~in ~~$1,000,000,000~~MGT inand ~~annual~~completed ~~gross~~the ~~revenue~~transaction with ~~and~~the ~~did~~principals ~~not~~of ~~have~~MGT ~~such~~under ~~amount~~the ~~as of~~proposal ~~December~~letter 31on February 20, 2015, ~~our~~to ~~last~~effectively ~~fiscal~~increase ~~year.~~the WeCompany’s ~~are~~equity ~~electing~~ ownership to ~~use~~50.1%. As consideration for acquiring the ~~extended~~additional ~~transition~~30.1% ~~period~~equity, ~~for~~the ~~complying~~Company ~~with~~issued ~~new~~1,200,000 orshares ~~revised~~of common stock ~~accounting~~with ~~standards~~a ~~under~~fair ~~Section~~market ~~102(b)(1)~~value of $60,000 to the ~~JOBS~~principals ~~Act~~and shareholders of MGT.

F-On May 6, 2015, the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and they agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. in the state of Tennessee and started the operation of distributing of existing and new line of products.

On February 2, 2017, the Cannabis Science GmbH, a subsidiary 90% owned by the Company and 10% owned by Dupetit Natural Products GmbH, has entered a Share Purchase Agreement with Jinvator BioMed GmbH (Jinvator), a German corporation, for 74.9% of the total issued and outstanding shares of Jinvator for ~~GOING~~three ~~CONCERN~~hundred thousand Euros (€ 300,000) which has a US dollar equivalent of $320,430. Jinvator developed a prototype called nanoGold-Test which is based on nano-particle technology for the detection of HIV in the early stage of infection. Patent has been submitted and pending for approval. The acquisition is pending on verification of key information.

~~The accompanying~~On ~~consolidated~~March ~~financial~~27, ~~statements~~2017, ~~have~~the ~~been~~Company ~~prepared~~entered inan ~~conformity~~agreement ~~with~~to ~~generally~~acquire the ~~accepted~~Assets ~~accounting~~of ~~principles~~AFA Research and Development, ~~which~~ ~~contemplate~~a ~~the~~California ~~continuation~~sole proprietorship of Aja Fonseca Arnold in the ~~Company~~research asand adevelopment of ~~going~~products ~~concern~~based on cannabinoid (CBD) and Tetrahydrocannabinol (THC) for patient care. ~~The~~ ~~Company~~As ~~reported~~consideration anfor ~~accumulated~~acquiring ~~deficit~~the Assets, which consist of ~~$139~~brands,~~971~~ pending trademarks,~~991and~~ trade-names, designs, medicinal products and formulations, client base, computer hardware ~~had~~and asoftware, ~~stockholders~~intellectual properties, inventory, equipment, supplies, supplier’s ~~deficit~~information and contacts, contracted rights, properties, patents, and distribution rights for a total sum of $4750,~~344,643~~000. asThe completion of ~~September~~assets 30acquisition is pending on verification of material information. In addition, ~~2016~~the Company engaged Aja Fonseca Arnold under a 5-year management agreement to continue the research and development of medicinal cannabis products for patient care with various ailments.

~~In view~~For ofother ~~the~~accounting ~~matters~~policies ~~described,~~please ~~there~~refer ~~is substantial doubt as~~ to the Company'’s ~~ability to continue as a going concern without a~~ ~~significant~~Form ~~infusion~~10-K ofwith ~~capital. At September 30, 2016,~~ the ~~Company~~SEC ~~had~~on ~~insufficient~~file ~~operating revenues and cash flow to meet its financial obligations. There can be~~ no ~~assurance that management will be successful in implementing its plans~~. ~~The~~ ~~consolidated~~000-28911 ~~financial~~161631274 ~~statements~~April do17, ~~not include any adjustments that might result from the outcome of this uncertainty~~2017.

We anticipate that we will have to raise additional capital to fund operations over the next 12 months. To the extent that we are required to raise additional funds to acquire research and growing facilities, and to cover costs of operations, we intend to do so through additional public or private offerings of debt or equity securities. There are no commitment or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming, or as to the terms of any such financings.F-6

~~Any~~The Company qualifies as an “emerging growth company” ~~future~~as ~~financing~~defined ~~may~~in ~~involve~~Section ~~substantial~~101 ~~dilution~~of tothe ~~existing~~Jumpstart ~~investors. We~~our ~~had~~Business ~~been~~Startups ~~relying~~Act on(“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2016, our ~~common~~last ~~stock~~fiscal year. We are electing to ~~pay~~use the ~~third~~extended ~~parties~~transition period for ~~services~~complying ~~which~~with ~~has~~new ~~resulted~~or inrevised ~~substantial~~accounting ~~dilution~~standards tounder ~~existing~~Section ~~investors~~102(b)(1) of the JOBS Act.

32. ~~FAIR~~ GOING ~~VALUE MEASUREMENTS AND DISCLOSURES~~CONCERN

~~ASC Topic~~The ~~820,~~accompanying ~~Fair~~consolidated ~~Value~~financial ~~Measurement,~~statements ~~establishes~~have abeen prepared ~~framework~~in ~~for~~conformity ~~measuring~~with ~~fair~~generally ~~value.~~accepted ~~That~~accounting ~~framework~~principles, ~~provides~~which acontemplate ~~fair~~the ~~value hierarchy~~continuation ~~that~~of ~~prioritizes~~ the ~~inputs~~Company toas ~~valuation~~a ~~techniques used to measure fair value~~going concern. The ~~hierarchy~~Company ~~gives~~reported ~~the~~an ~~highest~~accumulated ~~priority to~~deficit ~~unadjusted~~of ~~quoted~~$142,163,656 ~~prices~~and inhad ~~active~~a ~~markets~~stockholders’ ~~for~~deficit ~~identical~~of ~~assets or liabilities (Level 1 measurements) and the lowest priority~~$2,428,571 toas ~~unobservable~~of ~~inputs~~March ~~(Level~~31, ~~3 measurements)~~2017.

4In view of the matters described, there is substantial doubt as to the Company's ability to continue as a going concern without a significant infusion of capital. At March 31, 2017, ~~RELATED~~the ~~PARTY~~Company ~~TRANSACTIONS~~had insufficient operating revenues and cash flow to meet its financial obligations. There can be no assurance that management will be successful in implementing its plans. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~At September~~We ~~30,~~anticipate ~~2016,~~that awe ~~total~~will ofhave ~~$59,200~~to ~~(December~~raise ~~31,~~additional ~~2015:~~capital to ~~$816,945)~~fund inoperations ~~Accrued~~over ~~Management Fees Payable was due to~~ the ~~Company’s CEO/Director,~~next ~~Raymond~~12 Cmonths. To ~~Dabney.~~the Onextent ~~August~~that ~~10,~~we ~~2016,~~are arequired ~~total~~to ofraise ~~$975,407~~additional infunds ~~Management~~to ~~Fees~~acquire ~~Payable accumulated from February~~research ~~2012~~and togrowing ~~June 30~~facilities, ~~2016~~and ~~was converted into a Promissory Note~~ to ~~Raymond~~cover C.costs ~~Dabney, CEO/Director~~ of ~~the Company. The Company has partially reduced $250~~operations,~~000~~ aswe ~~result~~intend ofto ado ~~Debt~~so ~~Settlement~~through ~~Agreement~~additional ~~dated~~public ~~August~~or ~~10,~~private ~~2016~~offerings ~~by issuance~~ of ~~250,000,000 Rule 144~~ ~~restricted~~debt ~~common~~or ~~stock~~equity ~~at $0~~securities.~~001~~ There aare ~~share~~no commitment ~~with~~or aarrangements ~~loss~~for other offerings onin ~~settlement~~place, ofno ~~debt~~guaranties that any insuch ~~the~~financings ~~amount~~would ofbe $3forthcoming,~~550,000.~~ ~~The~~or ~~balance~~as ofto the ~~Promissory Note~~terms as of ~~September~~any ~~30,~~such ~~2016 was $725,407 (December 31, 2015: $0)~~financings.

~~At September~~Any ~~30,~~future ~~2016,~~financing amay ~~total~~involve ofsubstantial ~~$90,000~~dilution ~~(December~~to existing ~~31,~~investors. We ~~2015:~~had ~~Prepaid~~been ~~$45,000)~~relying inon ~~Accrued~~our ~~Management~~common ~~Fees~~stock ~~Payable~~to ~~was~~pay ~~due~~third toparties ~~the Company’s~~for ~~former~~services ~~COO/Director,~~which ~~Chad~~has ~~Johnson~~resulted in substantial dilution to existing investors.

~~At September~~3. ~~30,~~FAIR ~~2016,~~VALUE aMEASUREMENTS ~~total of $75,000 (December 31, 2015: $52,500) in Accrued Management Fees Payable was due to the Company’s~~AND ~~Director, Mario Lap.~~DISCLOSURES

~~At September~~ASC 30Topic 820, ~~2016~~Fair Value Measurement, establishes a ~~total~~framework offor ~~$60,000~~measuring ~~(December~~fair ~~31,~~value. ~~2015:~~That ~~Prepaid~~framework ~~$45,000)~~provides ina ~~Accrued~~fair ~~Management~~value ~~Fees~~hierarchy ~~Payable~~that ~~was~~prioritizes ~~due~~the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active ~~Company’s~~markets ~~COO/Director,~~for ~~Robert~~identical ~~Kane~~assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

~~At September 30, 2016, a total of $52,500 (December 31, 2015: $52,500) in loans payable was due to the Company’s CFO, Robert Kane, through his company, R Kane Holding Inc~~4., RELATED ~~secured~~PARTY ~~by a non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.~~TRANSACTIONS

At ~~September~~ 30March 31, ~~2016~~2017, ~~the~~a ~~Company~~total ~~owes~~of $11104,~~871~~200 (December 31, ~~2015~~2016: $014,200) toin ~~Crown~~Accrued ~~Baus~~Management ~~Capital~~Fees ~~Corp.,~~Payable ~~which~~was ~~advanced~~due ato ~~total of $11,871 for payment of~~ the Company’s ~~expenses in July~~CEO/Director, ~~August and September of 2015 with no interest and no security. Crown Baus Capital Corp. is a company controlled by~~ Raymond C. Dabney.

~~F-7~~At March 31, 2017, a total Prepaid management fees of $45,000 (December 31, 2016: Prepaid $52,500) advanced to the Company’s Director, Mario Lap.

~~As of~~At ~~September~~March 3031, ~~2016~~2017, ~~the~~a ~~Company~~total ~~owes~~of $~~101~~15,~~882~~000 (December 31, ~~2015~~2016: Prepaid $6130,~~902~~000) in ~~loan~~Accrued ~~payable~~Management toFees aPayable ~~stockholder,~~was ~~Interstate 101 that is non-interest bearing and~~ due onto ~~demand~~the ~~with~~Company’s ~~no security. The loan originated between April 1~~COO/Director, ~~2015~~Robert ~~and August 19, 2016 for various expenses of the Company~~Kane.

At ~~September~~ 30March 31, ~~2016~~2017, ~~the~~a ~~Company~~total ~~owes~~of $352,~~165~~500 (December 31, ~~2015~~2016: $352,~~165~~500) in ~~loan~~loans payable ~~toCastor~~was ~~Management~~due ~~Services~~to the Company’s CFO, aRobert ~~shareholder of~~Kane, ~~the~~through ~~Company~~his company, ~~with~~R noKane ~~interest~~Holding ~~and~~Inc., nosecured ~~security~~by a ~~and~~non-interest isbearing promissory note due onwithin ~~demand~~30 days of Michigan Green Technologies (50.1% ~~The~~controlled ~~loan~~by ~~originated~~the onCompany) ~~August~~liquidating shares 14in Cannabis Science, ~~2015~~Inc. ~~for~~to ~~expenses~~repay of the ~~Company~~debt.

At ~~September~~ 30March 31, ~~2016~~2017, athe ~~total~~Company ofowes $~~191~~11,~~344~~871 (December 31, ~~2015~~ 2016: $~~191~~11,~~344~~871) into ~~loans~~Crown ~~payable~~Baus ~~was~~Capital ~~due~~Corp., towhich ~~Bogat~~advanced ~~Family~~a ~~Trust~~total of $11,871 ~~Raymond Dabney~~for payment of the Company’s ~~Director~~expenses in July, August and ~~President/CEO~~September asof ~~trustee~~2015 with no interest and no security. Crown Baus Capital Corp. is a company controlled by Raymond C. Dabney.

~~At September 30, 2016, $86,964 (December 31, 2015: $66,847) was due to MJR BV, owned by Mario Lap director and director and officer of EU subsidiaries.~~ F-7

~~At September~~As 30of March 31, ~~2016~~2017, the Company owes $~~447~~101,882 (December 31, ~~2015~~2016: $~~447~~101,882) ~~was~~in ~~due~~loan payable to ~~Robert~~a ~~Melamede~~stockholder, ~~former~~Interstate ~~CEO~~101 that is non-interest bearing and due on demand with no security. The loan originated between April 1, 2015 and August 19, 2016 for various expenses of the Company.

At ~~September~~ 30March 31, ~~2016~~2017, the Company ~~held~~owes 7$3,~~500,000~~165 ~~common shares in the OmniCanna Health Solutions, Inc.~~ (~~prior~~December ~~to April 24~~31, ~~2014,~~ ~~the name was Endocan Corporation) (OTCBB~~2016: ~~ENDO) (“OmniCanna”) representing approximately 2.89% of the issued and outstanding shares of OmniCanna, of which 5,000,000 common shares were acquired at a fair market value of~~ $~~150~~3,~~000~~165) orin ~~$0.03~~loan ~~per~~payable ~~share~~to onCastor ~~December 12,~~Management ~~2012 and 2~~Services,~~500,000~~ ~~common shares were acquired at~~ a ~~fair~~shareholder ~~market value~~ of ~~$262,250~~the ~~or $0.1049 per share on February 8~~Company, ~~2013. The~~with ~~5,000,000~~no ~~common shares were received as consideration for the sale of its rights and~~ interest ~~in the Dupetit Natural Products GmbH joint-venture operating agreement to OmniCanna under an Asset Purchase Agreement~~ and ~~the~~no ~~2,500,000~~security ~~common shares were received as consideration for the sale of its rights~~ and ~~interest in the Maliseet joint-venture operating agreement to OmniCanna~~ ~~under~~is andue ~~Asset~~on ~~Purchase Agreement~~demand. The ~~value~~loan oforiginated ~~the~~on ~~shares~~August ~~at September 30~~14, ~~2016was~~2015 ~~determined to be $0.0089per share or $66,750 with the Company not recording any unrealized gainunder the Equity Investee rules~~ for ~~the~~expenses ~~nine months ended September 30, 2016and the value~~ of the ~~shares at December 31, 2015 was determined to be $0~~Company.~~0058 per share or $43,500.~~

~~On November~~At 5March 31, ~~2014~~2017, ~~the~~a ~~Company~~total ~~transitioned~~of ~~to equity method investee account for the OmniCanna shares pursuant to ASC 323 recording~~ $~~247~~191,~~500~~344 ~~as the fair value of the shares to its equity method investee account. On~~ (December 31, ~~2015, the Company recorded~~2016: ~~an impairment on the equity method investee account of~~ $~~114~~191,~~000~~344) in ~~relation~~loans topayable ~~the~~was ~~shares. Robert~~due ~~Kane,~~to ~~CFO~~Bogat ~~and~~Family ~~director of~~Trust, ~~the Company is also the CFO and a director~~ of ~~OmniCanna.~~which ~~Chad S. Johnson, Esq., COO, general counsel and a director is also a director and general counsel for Omni.~~ Raymond Dabney, ~~CEO is~~ the ~~controlling~~Company’s ~~shareholder~~Director ofand ~~OmniCanna Health Solutions,~~President/CEO ~~Inc~~as trustee.

~~For the~~At ~~Nine~~March ~~months~~31, ~~ended~~2017, ~~September~~$99,463 30(December 31, 2016: $93,885) ~~the~~was due ~~following~~to ~~related~~MJR ~~party~~BV, ~~stock-based~~owned ~~compensation~~by ~~was~~Mario ~~recorded:~~Lap director and director and officer of EU subsidiaries.

Related Party	Position	Amount
Raymond Dabney 1	CEO, President and Director	$	193,842
Dr. Allen Herman	Chief Medical Officer		25,500
Dr. Roscoe M. Moore, Jr	Chair of Scientific Advisory Board		302,000
Robert Kane	Director, COO from Sept. 14, 2016; CFO to Sept. 14, 2016		245,380
Chad S. Johnson, Esq.1	Former COO, General Counsel and Director to Sept. 14, 2016		215,380
Mario Lap1	Director		215,380
Benjamin Tam	CFO, Secretary and Director from Sept. 14, 2016		113,000
Alfredo Bernardi Dupetit	President & CEO of Cannabis Science Europe GmbH		51,000
		$	1,361,482

At March 31, 2017, $447 (December 31, 2016: $447) was due to Robert Melamede, former CEO.

1At March 31, 2017, a total of $52,160 ~~Including~~(December ~~compensation~~31, 2016: $23,378) in loans payable was due to ~~entities~~Drue ~~beneficially~~Young, ~~owned/control~~a byshareholder of the ~~related~~Company, ~~parties~~with no interest and no security and is due on demand. The loan originated from January 11, 2016 to March 31, 2017 for expenses of the Company.

~~F-8~~At March 31, 2017, a total of $20,502 (December 31, 2016: $20,502) in loans payable was due to Intrinsic Venture Corp., a shareholder of the Company, with no interest and no security and is due on demand. The loan originated from April 22, 2011 to December 31, 2014.

~~Raymond~~At March 31, 2017, the Company held 7,500,000 common shares ~~Dabney~~in the OmniCanna Health Solutions, ~~CEO~~Inc. ~~and~~(prior ~~Director~~to isApril a24, ~~controlling~~2014, ~~shareholder~~the name was Endocan Corporation) (OTCBB: ENDO) (“OmniCanna”) representing approximately 2.89% of the ~~Company~~issued and ~~Chad~~outstanding S.shares ~~Johnson~~of OmniCanna, ~~former~~of ~~COO/General~~which ~~Legal~~5,000,000 ~~Counsel/Director~~common shares were acquired at a fair market value of ~~the~~$150,000 ~~Company~~or ~~till~~$0.03 ~~September~~per 14share on December 12, ~~2016~~2012 and ~~COO/General~~2,500,000 ~~Legal~~common ~~Counsel/Director~~shares were acquired at a fair market value of ~~ImmunoClin~~$262,250 ~~Corporation~~or ~~(OTC:~~$0.1049 ~~IMCL)~~per share on February 8, ~~respectively~~2013. The 5,000,000 common shares were received as consideration ~~ImmunoClin~~for ~~performs~~the ~~laboratory~~sale ~~services,~~of ~~research~~its rights and ~~pharmaceutical~~interest ~~development~~in the Dupetit Natural Products GmbH joint-venture operating agreement to OmniCanna under an Asset Purchase Agreement and the 2,500,000 common shares were received as consideration for the ~~Company~~sale ~~through~~of its ~~wholly-owned~~rights and interest ~~subsidiary~~in ~~ImmunoClin~~the ~~Limited~~Maliseet ~~that~~joint-venture ~~operates~~operating aagreement ~~laboratory~~to OmniCanna under an Asset Purchase Agreement. The value of the shares at March 31, 2017 was determined to be $0.032 per share or $240,000 with the ~~London~~Company ~~Biosciences~~recording ~~Centre~~unrealized gain under the Equity Investee rules for the three months ended March 31, 2017 and the value of the shares at December 31, 2016 was determined to be $0.025 per share or $187,500.

~~See~~Convertible Notes Payable to Royalty Management Services ~~Note~~Corp., 6a ~~-Equity~~company ~~Transactions~~owned ~~for~~by ~~details~~a family member of ~~stock~~Mr. ~~issuances~~Raymond toC. ~~director~~Dabney, CEO/Director of the Company, entered into a management agreement with the Company on September 15, 2015 for accounting services, websites development and ~~officers~~maintenance, office management, management and payments for travel, promotion and entertainments, shareholders communications and payment services ~~rendered~~totaled $860,790 and $860,790 at March 31, 2017 and December 31, 2016 respectively. See Note 5.

~~Mario Lap,~~On aNovember ~~director~~5, of2014, the Company ~~and~~transitioned to ~~director~~equity ~~and~~method ~~officer~~investee ofaccount ~~its~~for ~~European~~the ~~subsidiaries,~~OmniCanna isshares ~~conducting~~pursuant ~~various~~to ~~business~~ASC ~~activities of~~323 ~~the~~recording ~~Company~~$247,500 inas ~~Spain~~the ~~under~~fair ~~his~~value ~~personal~~of ~~name~~the ~~and/or~~shares to ~~his~~its ~~personal~~equity ~~holding~~method ~~companies~~investee ~~MJR~~account. On BVDecember 31, ~~MLS~~2016, ~~Lap~~the BVCompany ~~and~~recorded ~~Cannabis~~an ~~Agency~~impairment ~~BV until~~on ~~such~~the ~~time~~equity asmethod ~~the~~investee account ~~Company~~of is$114,000 ~~able~~in relation to ~~establish~~the ashares. Robert ~~Spanish~~Kane, ~~subsidiary~~CFO toand ~~conduct~~director ~~its~~of ~~own~~the ~~business~~Company ~~operations~~is ~~and~~also ~~activities, including~~the ~~but~~CFO ~~not~~and ~~limited~~a ~~to:~~director of ~~operating~~OmniCanna. ~~lease~~Chad ~~for~~S. ~~farms~~Johnson, ~~asset purchases~~Esq., ~~office and equipment~~COO, ~~personnel~~general ~~employment~~counsel and ~~other business~~a ~~and~~director ~~operating~~is ~~activities~~also asa ~~may~~director beand ~~required~~general ~~from~~counsel ~~time-to-time. The~~for ~~Company anticipates having the Spanish subsidiary~~Omnicanna. ~~setup~~ Raymond ~~soon~~Dabney, atCEO ~~which~~has ~~time~~10.78% ~~Mario~~equity ~~Lap~~interest ~~under~~in ~~fiduciary~~Omniccanna ~~duty~~Health ~~will~~Solutions, ~~transfer~~Inc. ~~all~~as ~~business~~of ~~operating~~March ~~activities~~31, ~~agreements, and assets to the Company~~2017.

~~Alfredo Dupetit~~F-Bernardi, International Product Development and President & CEO of Cannabis Science Europe GmbH, is conducting product development through the purchase of cannabis products from his personal company, Dupetit Natural Products GmbH.8

~~Notes~~ ~~payable~~For tothe ~~Embella~~Three ~~Holdings~~months ~~Ltd.~~ended ~~totaled~~March ~~$1,108,896 and $1,108,896 at September 30, 2016 and December~~ 31, ~~2015~~2017, ~~respectively. As of September 30, 2016,~~ the ~~Company is in default on the promissory notes due and is negotiating with the debtor to extend~~following ~~the~~related ~~date.~~party ~~See~~stock-based ~~Note~~compensation 5.was recorded:

Notes payable to Intrinsic Capital Corp. totaled $231,260 and $231,260 at September 30, 2016 and December 31, 2015, respectively. See Note 5.


Related Party	Position		Amount
Alfredo Bernardi Dupetit	President & CEO of Cannabis Science Europe GmbH	$	415,000
		$	415,000

~~Between January~~ 1, ~~2015~~Including compensation to ~~March~~entities ~~7, 2015, R. Kane Holding Inc., a company~~ beneficially owned/control by ~~Mr. Robert Kane, director and CFO, had advanced $52,500 into Michigan Green Technologies, LLC, which is 50.1% controlled by~~ the ~~Company~~related ~~as Loan Payable to R. Kane Holding Inc.~~parties

~~On July~~See ~~25,~~Note ~~2014,~~6 ~~Bogat~~-Equity ~~Family~~Transactions ~~Trust,~~for ~~Raymond~~details ~~Dabney trustee, representing a majority~~ of ~~Series~~stock ~~A preferred stockholders, signed~~issuances ~~a resolution~~ to ~~approve~~director ~~an amendment to the certificate of designation preferences~~ and ~~rights~~officers for ~~Series~~services ~~A preferred shares~~rendered. Pursuant to the amendment filed with the Nevada Secretary of State, the voting rights of Series A preferred stockholders was changed from 1,000 votes per share to 67% of the total vote on all shareholder matters. No common stockholders voted on this amendment.

Mario Lap, a director of the Company and director and officer 5of its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MJR BV, MLS Lap BV and Cannabis Agency BV until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time. ~~NOTES~~The ~~PAYABLE~~Company anticipates having the Spanish subsidiary setup soon at which time Mario Lap under fiduciary duty will transfer all business operating activities, agreements, and assets to the Company.

~~As of~~Alfredo ~~September 30~~Dupetit-Bernardi, ~~2016,~~International aProduct ~~total of $2,065,563 (December 31, 2015: $1,406,513) of notes payable are due to stockholders that are~~Development ~~non-interest bearing~~ and ~~are~~President ~~due~~& 12CEO ~~months from the date~~ of ~~issue~~Cannabis ~~and~~Science ~~loan~~Europe ~~origination~~GmbH, ~~beginning~~is onconducting ~~January~~product ~~31,~~development ~~2012~~ through ~~June 30,~~the ~~2016.~~purchase ~~$1,340,156~~ of ~~the~~cannabis ~~Promissory~~products from ~~notes~~his ~~were~~personal ~~in default on September 30~~company, ~~2016.~~Dupetit ~~All~~Natural ~~promissory~~Products ~~notes are unsecured~~GmbH.

~~Notes payable~~On toAugust ~~Embella~~10, ~~Holdings~~2016, ~~Ltd.~~a ~~totaled~~total of $1975,~~108,896~~407 ~~and~~in ~~$1,108,896~~Management atFees Payable ~~September~~accumulated from February 2012 to June 30, 2016 ~~and~~was ~~December~~converted 31into a two-year Convertible Promissory Note to Raymond C. Dabney, ~~2015~~CEO/Director of the Company. At the election of the note holder, ~~respectively~~it can be converted into common stocks of the Company at the par value of $0.001 a share. The Company has fully recognized the conversion discounts of the Note as prepaid interest to Asthe maximum amount of ~~September~~$975,407 in accordance with ASC 470-20-30-8 and amortize it over the life of the Note. The Company has partially reduced $250,000 as result of a Debt Settlement Agreement dated August 10, 2016 by issuance of 250,000,000 Rule 144 restricted common stock at $0.001 a share. In addition, the Company ispaid $55,000 in ~~default~~expenses onfor Mr. Dabney in 2016. The balance of the ~~promissory~~Convertible Promissory ~~notes~~Note ~~due~~as ~~and~~of isMarch ~~negotiating~~31, ~~with~~2017 ~~the~~was ~~debtor~~$670,407 to(December ~~extend the~~31, ~~date~~2016: $670,407).

Notes payable to ~~Intrinsic~~Embella ~~Capital~~Holdings ~~Corp~~Ltd. totaled $~~231~~1,~~260~~ 108,896 and $~~231~~1,~~260~~108,896 at ~~September~~March 3031, ~~2016~~2017 and December 31, ~~2015~~2016, respectively. As of ~~September~~March 3031, ~~2016~~2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date. See Note 5.

~~F-9~~Notes payable to Intrinsic Capital Corp. totaled $231,260 and $231,260 at March 31, 2017 and December 31, 2016, respectively. See Note 5.

~~On August~~Between ~~10,~~January ~~2016~~1, a2015 ~~total~~to ofMarch ~~$975~~7,~~407~~ ~~in Management Fees Payable accumulated from February 2012 to June 30~~2015, ~~2016~~R. ~~was~~Kane ~~converted~~Holding ~~into~~Inc., a ~~Promissory~~company ~~Note~~owned toby ~~Raymond C~~Mr. ~~Dabney~~Robert Kane, ~~CEO/Director~~director ofand ~~the~~CFO, ~~Company.~~had ~~The~~advanced ~~Company has partially reduced~~ $~~250~~52,~~000~~500 asinto ~~result of~~Michigan aGreen ~~Debt Settlement Agreement dated August 10~~Technologies, ~~2016 by issuance of 250~~LLC,~~000,000~~ ~~Rule~~which ~~144 restricted common stock at $0.001 a share~~is ~~with a loss on settlement of debt in the amount of $3,550,000~~50.1% ~~The~~controlled ~~balance~~by of the ~~Promissory~~Company ~~Note~~ as ofLoan ~~September~~Payable ~~30,~~to ~~2016~~R. ~~was $725,407~~Kane ~~(December~~Holding ~~31, 2015: $0)~~Inc.

~~As of~~On ~~February~~July 725, ~~2016~~2014, ~~the~~Bogat ~~Company~~Family ~~has~~Trust, ~~settled~~with ~~the~~Raymond ~~balance~~Dabney as trustee, representing a majority of ~~$45~~Series A preferred stockholders,~~855~~ ~~promissory~~signed ~~note~~a ~~owed~~resolution to ~~Stacey~~approve R.an ~~Lewis~~amendment ~~since~~to ~~March~~the ~~21,~~certificate ~~2015~~of designation preferences and ~~issued~~rights ~~45,000,000~~for Series A preferred shares. Pursuant to the amendment filed with the Nevada Secretary of ~~common~~State, ~~stock~~the ~~pursuant~~voting torights aof ~~debt~~Series ~~settlement~~A ~~agreement~~preferred ~~with~~stockholders awas ~~fair~~changed ~~market~~from ~~value~~1,000 votes per share to 67% of the total vote ~~$634,500~~on all shareholder matters. No common stockholders voted on this amendment.

~~6. EQUITY TRANSACTIONS~~F-9

~~The Company is authorized to issue 3,000,000,000 shares of common stock with a par value of $0~~5.~~001 per share.~~ ~~These~~NOTES ~~shares have full voting rights. There were 2,327,855,296 and 1,581,855,296 issued and outstanding as of September 30, 2016 and December 31, 2015, respectively.~~PAYABLE

~~The Company~~As isof ~~also~~March ~~authorized~~31, to2017, ~~issue~~a ~~100~~total of $1,~~000~~590,~~000~~715 ~~shares~~(December 31, 2016: $1,506,745) of ~~common~~notes ~~stock,~~payable ~~Class~~are Adue ~~with~~mostly ato ~~par~~stockholders ~~value~~that ofare ~~$0.001~~non-interest ~~per~~bearing ~~share. These~~and are due 12 months from the ~~shares~~date ~~have~~of 10issue ~~votes~~and ~~per~~loan ~~share~~origination beginning on January 31, 2012 through December 31, 2016. ~~There~~ $1,340,156 of the Promissory notes were 0in ~~issued~~default ~~and~~on ~~outstanding~~March as31, 2017. As of ~~September~~March 3031, ~~2016~~2017, ~~and~~a total of $1,531,197 convertible promissory notes (December 31, ~~2015~~2016: $1,531,197) are convertible to common stock of the Company. All promissory notes are unsecured.

~~The Company~~Notes ispayable ~~also authorized~~ to ~~issue~~Embella ~~1,000,000~~Holdings ~~shares~~Ltd ofthat ~~preferred~~are ~~stock. These~~non-interest bearing ~~shares~~totaled ~~have~~$1,108,896 ~~full~~and ~~voting~~$1,108,896 ~~rights~~at ofMarch ~~67%~~31, ~~on all~~2017 ~~shareholder~~and ~~matters~~December ~~pursuant~~31, to2016, ~~amended~~respectively. As ~~certificate~~ of ~~designation~~March ~~filed~~31, ~~with~~2017, the Company ~~Nevada~~is ~~Secretary~~in ofdefault ~~State. There~~on ~~were 1,000,000~~the ~~issued~~promissory ~~and~~notes ~~outstanding~~due asand ofis ~~September~~negotiating ~~30,~~with ~~2016~~the ~~and~~debtor ~~December~~to ~~31,~~extend ~~2015~~the date.

~~As set~~Notes ~~out~~payable ~~below,~~to weIntrinsic ~~have~~Capital ~~issued~~Corp. ~~securities~~that inare ~~exchange~~non-interest bearing ~~for~~totaled ~~services~~$231,260 ~~properties~~and $231,260 at March 31, 2017 and ~~for~~December ~~debt~~31, ~~using~~2016, ~~exemptions~~respectively. ~~available~~As ~~under~~of March 31, 2017, the Company ~~Securities~~is ~~Act~~in ofdefault ~~1933~~on the promissory notes due and is negotiating with the debtor to extend the date.

~~During~~On August 10, 2016, a total of $975,407 ~~the~~in ~~nine~~Management ~~months~~Fees ~~ended~~Payable ~~September~~accumulated from February 2012 to June 30, 2016 was converted into a two-year Convertible Promissory Note to Raymond C. Dabney, CEO/Director of the Company. ~~issued~~At ~~153~~the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share. The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975,407 in accordance with ASC 470-20-30-8 and will amortize it over the life of the Note. The Company has partially reduced $250,000 as result of a Debt Settlement Agreement dated August 10, 2016 by issuance of 250,000,000 Rule 144 restricted common stock at $0.001 a share. In addition, the Company paid $55,000 in expenses for ~~services~~Mr. ~~under~~Dabney ~~various~~in ~~executive~~2016. ~~and~~The ~~consulting~~balance ~~agreements~~of the Convertible Promissory Note as ~~follows~~of March 31, 2017 was $670,407 (December 31, 2016: $670,407). In the three months ended March 31, 2017, the Company recorded $83,970 as interest for the amortization, conversion and payment.

On ~~February~~ October 1, 2016, ~~the~~a ~~Company~~total ~~entered~~of a$710,790 ~~management~~in ~~agreement~~Accounts ~~with~~Payable for amanagement ~~consulting~~fees ~~firm~~accumulated ~~and~~from ~~agreed~~January 2016 to ~~issue~~October 151,~~000,000~~ ~~shares~~2016 ofwas ~~R144~~converted into a one-year Convertible Promissory Note ~~restricted~~to ~~common~~Royalty ~~stock~~Management ~~with~~Services aCorp. ~~fair~~At ~~market~~the ~~value~~election of ~~$180~~the note holder,~~000~~ ~~for~~it ~~investor~~can ~~relation~~be ~~services~~converted into common stocks of the Company at the par value of $0.001 ~~The~~a ~~shares~~share ~~were~~or ~~issued~~other onmutually ~~April~~agreed ~~7, 2016~~upon price. The Company has not

~~On March~~recognized 8,the ~~2016,~~conversion discounts of the ~~Company~~Note ~~issued~~due ~~18,000,000~~to ~~shares~~the uncertainty ~~R144~~of ~~restricted~~the ~~common~~price ~~stock~~in toaccordance ~~Raymond~~with ~~Dabney,~~ASC ~~CEO~~470-20-25. The balance of the ~~Company~~Convertible ~~with~~Promissory ~~a fair~~Note ~~market~~as ~~value~~ of ~~$193~~March 31,~~842~~ ~~for~~2017 was ~~bonus~~$710,790 ~~under~~(December ~~November 5~~31, ~~2014~~2016: ~~management agreement~~$710,790).

On ~~March~~ 8December 31, 2016, ~~the~~$150,000 ~~Company~~in ~~issued~~Accounts 20Payable for management fees accumulated from November 1,~~000~~ 2016 to December 31,~~000~~ ~~shares~~2016 ~~R144~~was ~~restricted~~converted ~~common~~into ~~stock~~a one-year Convertible Promissory Note to ~~MLS~~Royalty Management ~~Lap~~Services BVCorp. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share or other mutually agreed upon price. The company ~~controlled~~has anot ~~director~~recognized the conversion discounts of the Note due to the uncertainty of the ~~Company~~price in accordance with aASC ~~fair~~470-20-25. ~~market~~The ~~value~~balance of ~~$215,380~~the ~~for~~Convertible ~~bonus~~Promissory ~~under~~Note ~~June~~as 24of March 31, ~~2013~~2017 ~~management~~was ~~agreement~~$150,000 (December 31, 2016: $150,000).

On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Chad Johnson, former COO/General Council till September 14, 2016 with a fair market value of $215,380 for bonus and services under November 25, 2014 agreement6. EQUITY TRANSACTIONS

OnThe Company is authorized to issue 3,000,000,000 shares of common stock with a par value of $0.001 per share. These shares have full voting rights. There were 2,443,355,296 and 2,350,355,296 issued and outstanding as of March 831, 2017 and December 31, 2016, ~~the~~respectively. ~~Company~~The ~~issued~~current 20authorized common stock of 3,000,000,000 shares ~~R144~~will ~~restricted~~not ~~common~~be ~~stock~~sufficient toif ~~Robert~~and ~~Kane,~~when ~~COO/director~~the debt holders of ~~the~~convertible ~~Company~~promissory ~~with~~notes elect to convert the adebts ~~fair~~into ~~market~~common ~~value~~shares. ofThe ~~$215,380~~Company intends to file for ~~bonus~~an ~~and~~increase ~~services~~in ~~under~~the ~~January~~number ~~20,~~shares ~~2015~~in ~~agreement~~authorized common stock once the required updated financial reportings have been filed with the Securities Exchange Commission.

~~On March~~The ~~22,~~Company ~~2016,~~is ~~the~~also ~~Company~~authorized ~~issued~~to 10issue 100,000,000 shares of ~~S-8 registered free-trading~~ common stock, ~~under~~Class ~~Scientific~~A ~~Advisory~~with ~~Board Agreement~~a par value of ~~the~~$0.001 ~~2016~~per ~~Equity~~share. These ~~Plan~~shares ~~with~~have a10 ~~fair~~votes ~~market~~per ~~value~~share. There were 0 issued and outstanding as of ~~$151~~March 31,~~000~~ 2017 and December 31, 2016.

~~On May 16, 2016, the Company issued 5,000,000 shares R144 restricted common stock and 2,500,000 shares of S~~F-~~8 registered free-trading common stock under an Application Development and Consulting Management Agreement of the 2015 Equity Award Plan with a fair market value of $86,250.~~10

~~On May~~The ~~16,~~Company ~~2016,~~is ~~the~~also ~~Company~~authorized ~~issued~~to 10issue 1,000,000 shares of ~~R144~~preferred ~~restricted~~stock. These ~~common~~shares ~~stock~~have ~~under~~full anvoting ~~International~~rights ~~Government~~of ~~Affairs~~67% ~~Board~~on all shareholder matters pursuant to amended certificate ~~Member~~of ~~Agreement~~designation filed with athe ~~fair~~Nevada ~~market~~Secretary ~~value~~ of ~~$151~~State. There were 1,000,000 issued and outstanding as of March 31, 2017 and December 31, 2016.

~~F-10~~As set out below, we have issued securities in exchange for services, properties and for debt, using exemptions available under the Securities Act of 1933.

~~On July~~During 26the three months ended March 31, ~~2016~~2017, the Company issued 758,~~500~~000,000 ~~shares of S-8 registered free-trading~~ common stock tofor aservices ~~consultant~~under ~~with~~various aexecutive ~~fair market value of $90,000 for bonus~~ and ~~services~~consulting ~~under~~agreements ~~October~~as ~~21, 2015 agreement.~~follows:

On ~~July~~ 26February 16, ~~2016~~2017, the Company issued 5,000,000 shares of ~~S-8~~R144 ~~registered~~restricted ~~free-trading~~ common stock to a consultant with a fair market value of $60350,000 for ~~bonus~~legal and general consulting services under ~~March~~a ~~16,~~consulting ~~2015~~ agreement dated January 13, 2017.

On ~~July~~ 26February 16, ~~2016~~2017, the Company issued 5 10,000,000 shares of S-8 registered free-trading common stock to a consultant with a fair market value of $60700,000 for ~~bonus~~legal and general consulting services ~~under~~pursuant ~~September~~to ~~18,~~a ~~2015~~consulting agreement dated January 13, 2017.

On ~~July~~ 26March 2, ~~2016~~2017, the Company issued 53,000,000 shares of R144 ~~S-8~~restricted ~~registered free-trading~~ common stock to a consultant with a fair market value of $60271,~~000~~500 for ~~bonus~~consulting ~~and~~ services ~~under~~pursuant ~~July~~to 6,a ~~2016~~two-year consulting ~~International Property Development Consulting Agreement~~agreement.

On ~~July~~ 26March 7, ~~2016~~2017, the Company issued 215,~~500~~000,000 shares of S-8 registered free- trading common stock tounder ~~Robert~~the ~~Kane,~~2016 ~~COO/director~~Equity ~~of the~~Award ~~Company~~Plan B with a fair market value of $301,~~000~~270,500 for ~~Management~~consulting ~~Fees~~ services under ~~January~~a ~~20,~~consulting ~~2015Executive~~agreement ~~Management~~dated ~~Agreement~~March 7, 2017.

On ~~August~~ 3March 13, ~~2016~~2017, the Company issued 210,~~500~~000,000 shares of S-8 registered free- trading common stock tounder athe ~~consultant~~2016 Equity Award Plan B with a fair market value of $38883,~~500~~000 for consulting services pursuant ~~under~~to ~~August~~a 3,consulting ~~2016~~agreement ~~Consulting~~dated ~~Agreement~~July 6 2016.

On ~~September~~ 14March 13, ~~2016~~2017, the Company issued 515,000,000 shares ofS-8 registered ~~R144~~free ~~restricted~~trading common stock tounder ~~Benjamin~~the ~~Tam,~~2016 ~~CFO/Secretary/Director of~~Equity ~~the~~Award ~~Company~~Plan B with a fair market value of $701,~~000~~324,500 for consulting services pursuant ~~under~~to ~~September~~a ~~14,~~consulting ~~2016~~agreement ~~Executive~~dated ~~Management~~April ~~Agreement~~29, 2015.

~~During~~ ~~the~~Stock ~~nine months ended September 30, 2016, the Company issued stock pursuant to debt settlement agreements as follows~~Options:

~~On February~~The 7,following ~~2016,~~options ~~the~~were ~~Company~~issued ~~entered into a partial debt settlement agreement with Stacey R. Lewis~~ to ~~retire $45,855 of~~ the ~~$75,044~~Company’s inV.P ~~promissory~~of ~~notes~~investor ~~originated on March 21~~relations, ~~2015~~CFO and ~~issued~~Director ~~45,000,000~~for ~~shares~~services ofunder ~~common stock to partially settle the debt for~~ a ~~loss~~September on16, ~~settlement~~2011 ~~of $588,645.~~agreement:

~~The aforementioned shares for the settlement of debts were issued without legend under an exemption under Rule 144~~(bi)~~(1)~~ of the ~~Act. Over~~option nine months has passed since the debts accrued on the books of the Company; the Seller is not now, and during the three-month period preceding the transaction has not been considered an “affiliate” of the Company. Furthermore, pursuant to ~~Rule~~purchase ~~144(d)(1)(i) the Company is~~100,000 ~~and~~common ~~has~~shares ~~been for a period of~~ at ~~least~~ten 90cents ~~days immediately before the proposed sale, subject to the reporting requirements of section 13 or 15~~(d$0.10) ofper the Securities and Exchange Act of 1934, and the proposed resale of the Shares in addition to the Company not being considered a shell company under Rule 144(i)(1). All relating shares were issued to settle the debts.share;

~~On August~~(ii) ~~10, 2016,~~ the ~~Company~~option ~~entered into a partial debt settlement agreement with Raymond C. Dabney, President/CEO/Director of the Company,~~ to ~~retire~~purchase ~~$250~~500,000 of the $975,407 in promissory notes originated on August 9, 2016 as result of unpaid management fees and bonuses from February 9, 2012 to June 30, 2016 with no interest, and issued 250,000,000 Rule 144 restricted common shares of ~~the Company~~ at athirty-five ~~deemed~~cents ~~price of~~ ($0.~~001~~35) per share; ~~as partial payment of the promissory note to settle the debt for a loss on settlement of $3,550,000.~~and

~~During~~ (iii) the ~~nine~~option ~~months~~to ~~ended~~purchase ~~September 30~~100,000 ~~2016,~~common ~~the~~shares ~~Company~~at ~~issued~~twenty ~~stock~~cents ~~pursuant~~($0.20) toper ~~amendment to a property license agreement as follow:~~share;

~~On January~~(iv) ~~11, 2016,~~ the ~~Company~~option ~~issued~~to 15purchase 1,~~500~~000,000 ~~shares of R144 restricted~~ common ~~stock~~shares toat ~~Apothecary~~fifty ~~Genetics~~cents ~~Investments with a fair market value of~~ ($~~181,350~~0.50) ~~for~~per ~~amendment to a property license agreement on February 9, 2012~~share.

~~During the~~On ~~nine~~January ~~months ended September 30~~13, ~~2016~~2017, the Company issued 7 10,~~500~~000,000 shares S-8 registered free-trading common stock ~~for~~under ~~legal~~an ~~retainer~~Option ~~services~~Agreement ~~under~~of ~~consulting~~2016 Equity Award Plan B with exercise ~~agreement~~price asat ~~follows:~~$0.05 and a fair market value of $700,000 to a consultant pursuant to a consulting agreement.

On ~~August~~ 3January 24, ~~2016~~2017, the Company issued 7 10,~~500~~000,000 shares of S-8 registered free-trading common stock tounder aan ~~legal~~Option ~~advisor~~Agreement asof ~~retainer~~ 2016 Equity Award Plan B with exercise price at $0.04 and a fair market value of $90815,000 ~~for~~to ~~legal~~Alfredo ~~services~~Dupetit-Bernardi, ~~under~~President/CEO ~~July~~of ~~22,~~Cannabis ~~2016~~Science ~~Consulting~~Europe ~~Agreement~~GmbH.

FOn March 27, 2017, the Company issued 15,000,000 shares S-118 registered free-trading common stock under the 2016 Equity Award Plan B with exercise price at $0.075 and a fair market value of $1,140,000 to a consultant pursuant to a five-year consulting agreement.

~~Stock Options:~~F-11

~~The following~~A ~~options~~summary ~~were~~of ~~issued~~the tostatus of the Company’s ~~V.P~~option grants as of ~~investor~~March ~~relations~~31, ~~CFO~~2017 and ~~Director~~the ~~for~~changes ~~services~~during ~~under~~the aperiod ~~September 16,~~then ~~2011~~ended ~~agreement~~is presented below:

(i) the option to purchase 100,000 common shares at ten cents ($0.10) per share;

	Shares		Weighted-Average Exercise Price
Outstanding December 31, 2016		11,700,000	$	0.0690
Granted		35,000,000	$	0.0606
Exercised		35,000,000	$	0.0606

Outstanding March 31, 2017		11,700,000	$	0.0680

Options exercisable at March 31, 2017		11,700,000	$	0.0680

~~(ii) the option to purchase 100~~1,700,000 ~~common~~ shares of these options at ~~twenty~~an ~~cents~~exercise (price of $0.~~20)~~415 ~~per~~a share;, do not expire and continuing indefinitely for the duration of existing management agreement and services thereunder with Robert Kane. The weighted average fair value at date of grant for options during year ended March 31, 2017 was estimated using the Black-Scholes option valuation model with the following:

(iii) the option to purchase 500,000 common shares at thirty-five cents ($0.35) per share; and


Average expected life in years for outstanding options	1.56	Years
Average risk-free interest rate	2.50	%
Average volatility	130.98	%
Dividend yield	0	%

~~(iv) the option to purchase 1,000,000 common shares at fifty cents ($0~~7.~~50)~~ EQUIPMENT ~~per~~AND ~~share.~~GREENHOUSE

On February 22, 2016, the Company issued 7,000,000 shares S-8 registered free-trading common stock exercised under Option Agreement of the 2015 Equity Award Plan with exercise price at $0.01 and a fair market value of $86,100 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of $307,500.

			Accumulated		March 31, 2017		Dec. 31, 2016
	Cost		Depletion		Net Book Value		Net Book Value
Computer	$	6,482		5,779		703		0
Software		5,000		5,000		0		0
		14,482		13,779		703		0
Greenhouse	$	330,026		—	$	330,026	$	0
Total	$	344,508	$	13,779	$	330,729	$	0

~~On February 22, 2016, the Company issued 6,500,000 shares S-~~8 ~~registered free-trading common stock exercised under Option Agreement of 2015 Equity Award Plan with exercise price at $0~~.01 ~~and~~PROPERTY aFARMING ~~fair market value of $79,950 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of $307,500.~~RIGHTS

On ~~February~~ 29March 24, 2016, the Company ~~issued~~entered 25a 15 years Joint Venture Agreement with the Ft. McDermitt Allotment land Allotees,~~000~~ which is on the Ft. McDermitt Tribal Reservation,~~000~~ ~~shares~~Raymond ~~S-8~~C. ~~registered~~Dabney University, ~~free--trading~~American ~~common~~Education ~~stock~~Consulting ~~under~~Group ~~Option~~and ~~Agreement~~Cannabis Science, Inc. for a total of ~~2016~~ten (10), one (1) acre parcels of land. ~~Equity~~The ~~Award~~project ~~Plan~~is ~~with~~designed ~~exercise~~to ~~price~~benefit atboth $0the Ft.01 McDermitt Tribe and aMembers, ~~fair~~and ~~market~~Allotment ~~value~~Allottees. Cannabis Science made two initial payments of $~~300~~50,000 for farming rights and initial development of two one (1) acre parcels of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to abe ~~consultant~~delivered ~~under~~and ~~management~~sold ~~agreement~~to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.

~~On March 22, 2016, the Company issued 15,000,000 shares of S~~F-~~8 registered free-trading common stock under Option Agreement of 2015 Equity Plan with exercise price at $0.01 and a fair market value of $226,500 to a consultant under management agreement.~~12

On ~~March~~ 22October 24, 2016, the Company ~~issued~~entered 5an Exclusive Master Facilitator Agreement with Members of Winnemucca Tribal Allotment,~~000~~ Free Spirit Organics,~~000~~ ~~shares~~LLC, ofAmerican ~~S-8~~Education ~~registered~~Consulting ~~free-trading~~Group ~~common~~and ~~stock~~Raymond ~~under~~C. ~~Option~~Dabney ~~Agreement~~University ofto ~~2016~~provide ~~Equity~~general ~~Plan~~support with ~~exercise~~developing, ~~price~~cultivating atand $0processing of Cannabis/Hemp on 320 Acres of leased land in Humboldt County, Nevada.01 The Company’s share is 40% of net profit derived from the sale and adistribution ~~fair~~of ~~market~~Cannabis/Hemp ~~value~~products grown and manufactured on these lands. Under the agreement, the Company will be provided one (1) acre of ~~$75~~land for research and development with placement of no more than 36,~~500~~000 tosquare afeet ~~consultant~~of ~~under~~greenhouses ~~management~~used ~~agreement~~for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is five (5) years and up to twenty-five (25) years.

On ~~March~~ 22November 12, 2016, the Company ~~issued~~entered an 10Exclusive Master Facilitator Agreement with the Members of Washoe Tribal Allotments in Douglas County,~~000~~ Nevada,~~000~~ ~~shares~~together ofwith Free ~~S-8~~Spirit ~~registered~~Organics, ~~free-trading~~LLC, ~~common~~American ~~stock~~Education ~~under~~Consulting ~~Option~~Group ~~Agreement~~and ofRaymond ~~2016~~C. Dabney University to provide general support with ~~Equity~~developing, ~~Plan~~cultivating and processing Cannabis/Hemp with ~~exercise~~Free ~~price~~Spirit atOrganics, $0LLC on Lot 20, one (1) acre parcel of leased land located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada.01 The Company’s share is 20% on all initial non-refundable deposits from external investor, and a10% of ~~fair~~net ~~market~~profit ~~value~~derived from the sale and distribution of ~~$151~~Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 tosquare afeet of ~~consultant~~greenhouses ~~under~~used ~~management~~for ~~agreement~~cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

On ~~March~~ 22December 18, 2016, the Company ~~issued~~enter six 15(6) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County,~~000~~ Nevada,~~000~~ ~~shares~~together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on 13 one (1) acre parcel of S-leased land, Lot 1, 2, 3, 4, 5, 7, 8, ~~registered~~9, ~~free-trading~~10, ~~common~~11, ~~stock~~12, ~~under~~13 ~~Option~~and ~~Agreement~~14, located in the allotment cc183, a portion of ~~2016~~the ~~Equity~~SE ~~Plan~~¼ ~~with~~of ~~exercise~~section ~~price~~15, attownship 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $040,000 per acre Good Faith Non-Refundable Deposit per development site.01 The Company’s share is 20% on all initial non-refundable deposits from external investor, and a10% ~~fair~~of ~~market~~net ~~value~~profit derived from the sale and distribution of ~~$226,500~~Cannabis/Hemp toproducts grown aand ~~consultant~~manufactured ~~under~~on ~~management~~the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

On ~~March~~ 22December 21, 2016, the Company ~~issued~~enter two 10(2) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County,~~000~~ Nevada,~~000~~ ~~shares~~together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on two (2) one (1) acre parcel of ~~S-8~~leased ~~registered~~land, ~~free~~Lot 6 and 21, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-~~trading~~Refundable ~~common~~Deposit ~~stock~~per ~~under~~development ~~Scientific~~site. ~~Advisory~~The ~~Board~~Company’s share is 20% on all initial non-refundable deposits from ~~Agreement~~external investor, and 10% of net profit derived from the ~~2016~~sale ~~Equity~~and ~~Plan~~distribution ~~with~~of aCannabis/Hemp ~~fair~~products ~~market~~grown ~~value~~and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of ~~$151~~land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

On March 22, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at $0.01 and a fair market value of $75,500.

			Accumulated		March 31, 2017		Dec. 31, 2016
	Cost		Depletion		Net Book Value		Net Book Value
Property Farming Rights
Fort McDermit Allottees Land	$	50,000	$	3,056	$	46,944	$	47,778
Washoe Tribal Allotment Lands		640,000		7,452		632,548		638,948
		690,000	$	10,508		679,492		686,726
Operating capital for Washoe Lands	$	60,000			$	60,000	$	—
Operating capital for Winnemucca Lands		65,000		—		65,000		65,000
	$	125,000	$	—		125,000		65,000
Total	$	815,000	$	10,508	$	804,492	$	751,726

~~On May 10, 2016, the Company issued 18,000,000 shares of S~~F-8 registered free-trading common stock for balance of shares exercised under an Option Agreement dated February 22, 2016 under 2016 Equity Award Plan with exercise price at $0.01 and a fair market value of $221,400 to a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of $307,500.13

FAll equipment is stated at cost. Maintenance and repairs are charged to expense as incurred and the cost of renewals and betterments are capitalized. Depreciation is computed using the straight-12line method over the estimated lives of the related assets, 2 years for computer, 2 years for software, 5 years for equipment and laboratory equipment and 3 years for automobile.

~~On May~~All ~~10,~~property ~~2016,~~farm ~~the~~rights ~~Company~~are ~~issued 18,500,000 shares of S-8 registered free-trading common stock for balance of shares exercised~~amortized ~~under~~over anthe ~~Option~~term ~~Agreement dated February 22, 2016 under 2016 Equity Award Plan with exercise price at $0.01 and a fair market value~~ of ~~$227,550~~each torespective ~~a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of $307,500~~agreements.

~~On May 16, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at $0~~9.01 EQUITY ~~and~~METHOD ~~a fair market value of $75,500 to a consultant under management agreement.~~INVESTEE

On ~~May~~ 16November 5, ~~2016~~2014, the Company ~~issued~~accounted 10for its investment and loans in OmniCanna Health Solutions,~~000,00~~ ~~shares~~Inc. of(formerly ~~S-8~~Endocan ~~registered~~Corporation) ~~free-trading~~using ~~common~~the ~~stock~~equity ~~under~~method ~~Option~~pursuant ~~Agreement~~to ofASC ~~2016~~323 ~~Equity~~– ~~Award~~Investments ~~Plan~~– ~~with~~Equity ~~exercise~~Method ~~price~~and atJoint $0Ventures.01 In ~~and~~accordance with ASC 323, when the Company does not have a ~~fair~~controlling financial ~~market~~interest ~~value~~in ofan ~~$151,000~~entity tobut ~~Alfredo~~exerts ~~Bernardi~~significant ~~Dupetit~~influence over the entity’s operating and financial policies, ~~President~~the Company &accounts ~~CEO~~for its investment in accordance with the equity method of accounting. This generally applies to cases in which ~~Cannabis~~the ~~Science~~Company ~~Europe~~owns ~~GmbH~~a voting or economic interest of between 20 and 50 percent.

OnThe accounting using the equity method is in conjunction ~~May~~with ~~16,~~appointment ~~2016,~~of Raymond Dabney as CEO and director of the Company ~~issued~~on 15November 5,~~000~~ 2014,~~000~~ ~~shares~~in addition to Mr. Dabney being a controlling shareholder of ~~S-8~~the ~~registered~~Company ~~free-trading~~since ~~common~~September ~~stock~~2009 ~~under~~and ~~Option~~a ~~Agreement~~10.78% ofequity ~~2016~~interest in OmniCanna since June 2013. Benjamin Tam, CFO and ~~Equity~~director ~~Award~~and ~~Plan~~Robert ~~with~~Kane, ~~exercise~~COO ~~price~~and atdirector ~~$0.01~~of the Company are also the CFO and adirector ~~fair~~and ~~market~~COO ~~value~~and director of ~~$264~~Omnicanna. Therefore,~~000~~ the Company was deemed to ahave ~~consultant~~significant ~~under~~influence ~~management~~and ~~agreement~~control of OmniCanna Health Solutions, Inc.

On ~~May~~ 16November 5, ~~2016~~2014, the Company ~~issued~~recorded $247,500 10in marketable securities and $85,~~000,000~~277 ~~shares~~(based on currency converted as of ~~S-8~~March ~~registered~~31, ~~free-trading~~2017) ~~common~~in ~~stock~~loans ~~under~~to ~~Option~~OmniCanna ~~Agreement~~and ofto ~~2016~~its ~~Equity~~equity ~~Award~~method ~~Plan~~investee ~~with~~account ~~exercise~~in ~~price~~accordance atwith $0ASC 323.01 An ~~and~~unrealized again ~~fair~~on ~~market~~the ~~value~~equity method account of $~~176~~52,~~000~~500 was recognized for the three months ended March 31, 2017 in addition to a ~~consultant~~unrealized ~~under~~gain ~~management~~on ~~agreement~~the equity method investee account of $144,000 was recognized for the year ended December 31, 2016 in the value of Omnicanna marketable securities.

~~On July 26, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at $0~~10.01 GOODWILL and aINTANGIBLE ~~fair market value of $76,500 to a consultant under July 4, 2016 management agreement.~~ASSETS

On September 27, 2016, the Company entered an Option Agreement with Benjamin Tam, CFO/Secretary/Director of the Company under 2016 Equity Award Plan B at exercise price of $0.01 to issue 10,000,000 shares of S-8 registered free-trading common stock with a fair market value of $143,000. The shares were exercised on September 27, 2016 and issued on October 7, 2016.


	March 31, 2017			December 31, 2016
Intellectual assets, primarily intellectual property	$	660,299		$	660,299
Goodwill		170,688			170,688
Less: accumulated amortization		(499,049	)		(488,299	)
Less: Impairment of Goodwill		(170,689	)		(170,689	)
Total intangible assets, net	$	161,250		$	172,000

~~On September~~Intangible ~~27,~~assets ~~2016,~~are ~~the~~stated ~~Company~~at ~~entered~~fair anvalue ~~Option~~on ~~Agreement~~the ~~with~~date aof purchase ~~consultant~~less ~~under~~accumulated ~~2016 Equity Award Plan B at exercise price of $0~~amortization.01 toAmortization ~~issue~~is ~~15,000,000~~computed ~~shares~~using ofthe Sstraight-8line ~~registered~~method ~~free-trading~~over ~~common~~the ~~stock~~estimated ~~with~~lives ~~a fair market value~~ of ~~$214,500.~~the related ~~The~~assets ~~shares were~~(5 ~~exercised~~years onfor ~~September~~both ~~27,~~intellectual ~~2016~~assets and ~~issued on October 7, 2016~~Goodwill).

~~On September 27, 2016, the Company entered an Option Agreement with a consultant under 2016 Equity Award Plan B at exercise price of $0.01 to issue 10,000,000 shares of S~~F-~~8 registered free-trading common stock with a fair market value of $143,000. The shares were exercised on September 27, 2016 and issued on October 7, 2016.~~14

~~On September 27, 2016, the Company entered an Option Agreement with a consultant under 2016 Equity Award Plan B at exercise price of $0~~11.01 toPREPAID ~~issue~~EXPENSES ~~15,000,000~~AND ~~shares~~DEPOSITS ofHELD ~~S-8~~WITH ~~registered free-trading common stock with a fair market value of $214,500. The shares were exercised on September 27, 2016 and issued on October 7, 2016.~~RMS

On ~~September~~ 27October 1, 2016, the Company entered ana ~~Option~~Paying ~~Agreement~~Agent Agreement with aRoyalty ~~consultant~~Management ~~under~~Services ~~2016~~Corp. ~~Equity~~(RMS) ~~Award~~for ~~Plan~~holding Bfunds atand ~~exercise~~making ~~price of~~payment ~~$0.01~~for toexpenses ~~issue~~and ~~10,000,000~~commitments ~~shares~~ of ~~S-8~~the ~~registered~~Company. The ~~free-trading~~Company ~~common~~has ~~stock~~entered a Management Agreement with aRMS ~~fair~~since ~~market~~September ~~value~~15 of2016 ~~$143~~for management,~~000.~~ ~~The~~investors’ ~~shares~~and shareholders’ ~~were~~communications, ~~exercised~~website ondevelopment, ~~September~~database 27management, ~~2016~~accounting and ~~issued~~management onof ~~October~~all 7,activities ~~2016~~such as travel and conference. All the expenses related to the services for the Company are included as part of the management fees.

~~On September~~March 2731, ~~2016,~~2017 ~~the~~December ~~Company entered an Option Agreement with a consultant under 2016 Equity Award Plan B at exercise price of $0.01 to issue 10~~31,~~000,000~~ ~~shares of S-8 registered free-trading common stock with a fair market value of $143,000. The shares were exercised on September 27,~~ 2016 ~~and issued on October 7, 2016.~~

On September 27, 2016, the Company entered an Option Agreement with a consultant under 2016 Equity Award Plan B at exercise price of $0.01 to issue 10,000,000 shares of S-8 registered free-trading common stock with a fair market value of $143,000. The shares were exercised on September 27, 2016 and issued on October 7, 2016.

Prepaid consulting expenses	$	138,000	$	141,750
Prepaid Legal fees		90,000		90,000
Prepaid rent		244		244
Prepaid management fees		47,500
Deposits held with RMS		—		576,520
Total Prepaid expenses and Deposits held with RMS	$	275,744	$	808,514

~~F-13~~12. COMMITMENTS

~~On September~~The ~~27, 2016, the~~ Company ~~entered~~has anlease ~~Option~~commitments ~~Agreement with a consultant~~ for ~~International~~its ~~Property~~European ~~Development~~ operations under ~~2016 Equity~~private ~~Award~~companies, ~~Plan~~MLS Lap B.V. atand ~~exercise~~MJR ~~price~~B.V. ofowned ~~$0.01~~and tocontrolled ~~issue~~by 10Mario Lap,~~000,000~~ ~~shares~~director of ~~S-8~~the ~~registered~~Company ~~free-trading~~and ~~common~~director ~~stock with a fair~~and ~~market~~officer ~~value~~ of ~~$143,000~~EU subsidiaries. ~~The~~Negotiations ~~shares~~are ~~were~~ongoing ~~exercised~~in onregards ~~September~~to ~~27,~~preparing ~~2016~~finalized ~~and~~agreements ~~issued~~between onthe ~~October~~Company ~~25,~~and ~~2016~~Mr. Lap’s companies.

~~On September 27, 2016, the Company entered an Option Agreement with a consultant for International Government Affairs under 2016 Equity Award Plan B at exercise price of $0~~13.01 SUBSEQUENT ~~to issue 5,000,000 shares of S-8 registered free-trading common stock with a fair market value of $71,500. The shares were exercised on September 27, 2016 and have not been issued.~~EVENTS

~~A summary~~On ofApril ~~the~~18, ~~status~~2017, of the Company’s issued ~~option~~10,000,000 ~~grants~~shares asS-8 ofregistered ~~September~~free-trading ~~30,~~common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.02 and ~~the~~a ~~changes~~fair ~~during~~market ~~the~~value ~~period~~of ~~then~~$829,000 ~~ended is~~to ~~presented~~Chief ~~below:~~Medical Officer, Dr. Allen Herman.

	Shares		Weighted-Average Exercise Price
Outstanding December 31, 2015		4,200,000	$	0.195
Granted		275,000,000	$	0.010
Exercised		275,000,000	$	0.010
Expired		2,500,000	$	0.040
Outstanding September 30, 2016		1,700,000	$	0.41
Options exercisable at September 30, 2016		1,700,000	$	0.41

On April 27, 2017, the Company entered a five-year Research Collaboration Agreement with DFCI for a research project to develop and investigate the use of Cannabinolds to cure various forms of cancer and investigate synergies with radiotherapy and immunotherapy. In consideration for this agreement and performance of the research, the Company is obligated to pay DFCI a total of $1,834,062 over the life of the agreement with $159,287 due at signing and $418,683 to be paid at each anniversary of the agreement for the next four years.

~~1,700,00 shares~~On ofMay ~~these~~8, ~~options~~2017, atthe anCompany ~~exercise~~issued ~~price of $0.415 a share~~7,000,000 shares ~~do not expire and continuing indefinitely for the duration~~ of ~~existing~~ ~~management~~R144 ~~agreement~~restricted ~~and~~common ~~services~~stock ~~thereunder~~ with ~~Robert~~a ~~Kane. The weighted average~~ fair market value ~~at date~~ of ~~grant for options during year ended September 30~~$469,000 ~~2016~~pursuant ~~was~~to ~~estimated~~a ~~using the Black~~one-~~Scholes~~year ~~option~~consulting ~~valuation model with the following:~~agreement.

Average expected life in years for options with no expiry	unlimited Years
Average risk-free interest rate		2.00	%
Average volatility		90	%
Dividend yield		0	%

On May 10, 2017, the Company paid €60,000 to the principal shareholder of Jinvator BioMed GmbH (Jinvator) as deposit for the purchase of the 74.9 % equity interest in Jinvator.

7.On May 17, 2017, the Company issued ~~PROPERTY~~1,500,000 ~~FARMING~~shares ~~LICENSE~~of R144 restricted common stock with a fair market value of $93,600 pursuant to a one-year consulting agreement.

~~On March 24, 2016, the Company entered a~~ F-15 years Joint Venture License Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made two initial payments of $50,000 for licensing and initial development of two one (1) acre parcels of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.

8On May 18, 2017, the Company entered an Exclusive Master Facilitator Agreement with Winnemucca Tribal MBS of Nevada, Free Spirit Organics, LLC (FSO), American Education Consulting Group, Raymond C. Dabney University (RCDU), American States University and Royalty Management Services Corp. (RMS) to ~~DEPOSITS~~lease and develop 250 Acres of land located in Holt, California for 15 years. As a master facilitator, the Company will provide general support with developing, cultivating and processing Industrial Hemp for RCDU and FSO on the property. Pursuant to the agreement, the Company and RMS are responsible for a $400,000 non-refundable deposit and the development and operations on the property on 50-50 basis. Additionally, the Company will share 40% of net profit as investor with RMS and retain 5% of net profit as master facilitator.

On ~~February~~ 9May 31, ~~2012~~2017, ~~the~~$375,000 ~~Company~~in ~~signed~~Accounts aPayable ~~license~~for ~~agreement with Apothecary to produce several Cannabis Science Brand Formulations~~management ~~for~~fees ~~the~~accumulated ~~California~~from ~~medical~~January ~~cannabis market. As well~~1, ~~Apothecary~~2017 ~~will~~to ~~provide~~May ~~research~~31, ~~and~~2017 ~~development~~was ~~facilities~~settled ~~with~~by ~~full~~issuance ~~circle operations~~of ~~including~~ a ~~California~~one-year ~~laboratory~~Convertible ~~facility~~Promissory ~~for~~Note ~~internal~~to ~~research and development, along with 16 unique genetic strains~~Royalty ~~specifically~~Management ~~generated~~Services ~~and~~Corp. ~~maintained~~At ~~by a cancer survivor who recognizes~~ the ~~importance~~election of ~~proper~~the ~~growth~~note ~~and~~holder, ~~breeding~~it incan ~~addition to~~be ~~investing~~converted ~~$250,000~~into incommon ~~research~~stock ~~and~~of ~~development in~~ the ~~first~~Company 24at ~~months. Apothecary~~the ~~failed~~par ~~to meet several contract provisions~~value ~~including~~of ~~investing~~ $~~250,000~~0.001 ~~in R&D, setting up~~ a ~~laboratory~~share ~~facility,~~or ~~and~~other ~~reporting~~mutually ~~and~~agreed ~~remitting~~upon ~~license fees owing to the Company~~price. On ~~November~~The ~~20, 2014, the~~ Company ~~signed~~has anfully ~~amendment~~recognized to the ~~license~~conversion ~~agreement. Pursuant~~discount toof the ~~amendment,~~Note as ~~the~~prepaid ~~Company~~interest ~~was~~ to ~~acquire~~the ~~all~~maximum ~~property,~~amount ~~building, and equipment~~ of ~~Apothecary in exchange for 14~~$375,~~500,~~000 ~~Rule~~in ~~144~~accordance ~~restricted stock~~ with aASC ~~fair~~470-20-30-8 ~~market value of $971,500 which was spent mostly in research~~ and ~~development~~amortize ~~for~~it ~~cannabis~~over ~~growth on~~ the ~~Northern California~~life ~~property.~~of ~~The Company wrote off~~ the ~~deposit as Loss on investment for the period ended September 30, 2016~~Note.

F-1416

~~On January~~ITEM 112. ~~2016, the Company signed a second amendment to the license agreement and issued 15,500,000 shares of Rule 144 restricted stock, held in escrow by the Company~~MANAGEMENT’sS ~~attorney,~~DISCUSSION ~~with~~AND aANALYSIS ~~fair~~OF ~~market~~FINANCIAL ~~value~~CONDITION ofAND ~~$181,350,~~RESULTS ~~until~~OF the title has been transferred to the company. Pursuant to the second amendment the Company waives prior Royalties owed under any Section of any previous Agreements, and Apothecary shall make business introductions in Jamaica for the Company to work with government licensed growers, laboratories, doctors, and any other mutually agreeable business introductions. Apothecary will immediately sign and transfer ownership of the Northern California Property to the Company and repay and discharge a lien on the property within 12 months signing the second amendment.OPERATIONS

~~The Company~~This ~~recorded~~section ~~an equivalent deposit~~ of ~~$181,350~~this ~~for~~report ~~the~~includes a ~~ninemonths~~number ~~ended~~of ~~September~~forward-looking ~~30,~~statements ~~2016~~that ~~until~~reflect ~~the~~our ~~acquisition~~current ofviews ~~assets closes,~~with ~~which~~respect ~~was~~to ~~anticipated~~future inevents ~~July~~and offinancial ~~2016~~performance. Forward-looking Instatements ~~the~~are ~~month~~often ofidentified ~~July~~by ~~2016,~~words ~~Apothecary~~like: ~~Genetics~~believe, ~~Investments~~expect, ~~LLC~~estimate, ~~breached~~anticipate, ~~the~~intend, ~~amended~~project and ~~agreement~~similar byexpressions, ~~refusing~~or towords ~~transfer~~which, ~~the~~by ~~Northern~~their ~~California~~nature, ~~property~~refer to ~~the~~future ~~Company~~events. You ~~and~~should ~~demanded~~not ~~additional~~place ~~payment~~undue ~~for~~certainty ~~the~~on ~~property.~~these ~~The~~forward-looking ~~Company~~statements, ~~declined~~which toapply ~~pay~~only ~~additional~~as ~~funds~~of ~~for~~ the ~~property~~date ~~and~~of ~~put~~this ~~the project on hold~~report. These ~~All~~forward-looking ~~the~~states ~~15,500,000~~are ~~Rule~~subject ~~144~~to ~~restricted~~certain ~~common~~risks ~~shares~~and ~~are~~uncertainties ~~held~~that incould ~~escrow~~cause ~~until~~actual ~~further~~results ~~decision~~to bydiffer ~~the~~materially ~~management~~from ofhistorical ~~the~~results ~~Company~~or our predictions.

~~9. EQUITY~~Overview ~~METHOD~~of ~~INVESTEE~~the Company’s Business

~~On November~~Cannabis 5Science, ~~2014~~Inc. (formerly Gulf Onshore, Inc.) (“We” or “the Company”), ~~accounted~~was ~~for~~incorporated ~~its~~under ~~investment~~the ~~and~~laws ~~loans~~of inthe ~~OmniCanna~~State ~~Health~~of ~~Solutions~~Colorado, on ~~Inc.~~February ~~(formerly~~29, ~~Endocan~~1996, ~~Corporation) using~~as ~~the~~Patriot ~~equity~~Holdings, ~~method~~Inc. On ~~pursuant~~August to26, ~~ASC~~1999, ~~323~~the –Company ~~Investments~~changed –its ~~Equity~~name ~~Method~~to ~~and~~National ~~Joint~~Healthcare Technology, ~~Ventures~~Inc. InOn ~~accordance with~~June ~~ASC~~6, ~~323~~2007, ~~when~~ the Company ~~does~~changed ~~not~~its ~~have~~name afrom ~~controlling~~National ~~financial~~Healthcare ~~interest~~Technology, inInc., anto ~~entity~~Brighton ~~but~~Oil & ~~exerts~~Gas, ~~significant~~Inc., ~~influence~~and ~~over the~~converted ~~entity’s~~to ~~operating~~a ~~and~~Nevada ~~financial~~corporation. On ~~policies~~March 25, 2008 the Company ~~accounts~~changed ~~for~~ its ~~investment~~name into ~~accordance~~Gulf ~~with the equity method~~Onshore, ~~of accounting~~Inc. On ~~This~~April ~~generally~~7, ~~applies~~2009, ~~to cases in which~~ the Company ~~owns~~changed aits ~~voting~~name orto ~~economic~~Cannabis ~~interest~~Science, ~~of between 20 and 50 percent~~Inc.

~~The accounting~~Cannabis ~~using~~Science, ~~the~~Inc. ~~equity~~is ~~method~~at isthe inforefront of ~~conjunction~~medical ~~with~~cannabis ~~appointment~~research ofand ~~Raymond~~development. The ~~Dabney~~Company asworks ~~CEO~~with ~~and~~world ~~director~~authorities ofon ~~the~~phytocannabinoid ~~Company~~science ontargeting ~~November~~critical 5illnesses, ~~2014,~~and inadheres ~~addition~~ to ~~Mr.~~scientific ~~Dabney~~methodologies ~~being~~to adevelop, ~~controlling~~produce, ~~shareholder~~and ofcommercialize ~~the~~phytocannabinoid-based ~~Company~~pharmaceutical products. In ~~since~~summary, ~~September~~we ~~2009~~are ~~and~~dedicated ato ~~controlling shareholder~~the creation of ~~OmniCanna~~cannabis-based ~~Health Solutions~~medicines, ~~Inc.~~both ~~since~~with ~~June~~and ~~2013. Therefore~~without psychoactive properties, to ~~the~~treat ~~Company~~disease ~~was~~and ~~deemed~~the tosymptoms ~~have~~of ~~significant~~disease, ~~influence and~~as ~~control~~well ofas ~~OmniCanna~~for ~~Health~~general ~~Solutions,~~health ~~Inc~~maintenance.

~~On November~~Cannabis 5Science, ~~2014~~Inc., ~~the~~takes ~~Company~~advantage of ~~recorded~~its ~~$247,500~~unique inunderstanding ~~marketable~~of ~~securities~~metabolic ~~and~~processes ~~$85,631~~to ~~(based~~provide onnovel ~~currency~~treatment ~~converted~~approaches asto a number of ~~September~~illnesses for which current ~~30,~~treatments ~~2016)~~and understanding remain unsatisfactory. The Company works with leading experts in ~~loans~~drug todevelopment, ~~OmniCanna~~medicinal characterization, ~~Health~~and ~~Solutions~~clinical research to develop, ~~Inc.~~produce, ~~(hereinafter~~and ~~referred~~commercialize asnovel ~~“OHS”)~~therapeutic toapproaches ~~its~~for ~~equity~~the ~~method~~treatment ~~investee~~for ~~account~~illnesses incaused ~~accordance~~by ~~with~~infections ~~ASC~~as ~~323~~well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

~~An impairment~~Cannabis onScience, ~~the~~Inc. ~~equity~~takes ~~method investee account~~ advantage of ~~$48,750~~its ~~was~~unique ~~recognized~~understanding ~~for~~of ~~the~~metabolic ~~nine~~processes ~~months ended September 30, 2015 due~~ to ~~the~~ ~~fluctuation~~provide ininnovative ~~the~~treatment ~~value~~options offor ~~OHS’s~~unmet ~~marketable~~medical ~~securities~~needs.

~~10.~~Cannabis use has an extensive history ~~GOODWILL~~dating back thousands of years, and ~~INTANGIBLE~~currently ~~ASSETS~~there are thousands of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate.

	September 30, 2016			December 31, 2015
Intellectual assets, primarily intellectual property and goodwill	$	830,988		$	830,988
Less: accumulated amortization		(503,152	)		(445,299	)
Total intangible assets, net	$	327,836		$	385,689

At Cannabis Science, we use an inquiring approach to discover and develop novel cannabinoid-based therapies to improve patients’ lives. From the initiation, our founders have been committed to fostering and maintaining a bold, pioneering spirit fostering the true nature of innovation from which cutting edge ideas flourish and translate into evidence-based solutions.

~~Intangible assets~~We are ~~stated~~dedicated atto ~~fair~~working ~~value~~closely with onlocal, ~~the~~national ~~date~~and ofinternational ~~purchase~~regulatory ~~less~~agencies ~~accumulated~~to ~~amortization.~~provide ~~Amortization~~access isto ~~computed~~high ~~using~~quality, ~~the~~first ~~straight-line~~class cannabinoid pharmaceuticals ~~method~~to ~~over~~those ~~the~~critically ~~estimated~~in ~~lives~~need of new treatments for life threatening and debilitating conditions. Cannabis Science’s clinical trial material comes from the ~~related~~cultivation ~~assets~~and (5production ~~years~~facilities ~~for~~that ~~both~~are ~~intellectual~~GMP ~~assets~~compliant, surpassing high quality standard industrial and ~~Goodwill)~~food processing requirements.

~~11.~~The Company works with leading experts ~~COMMITMENTS~~in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.

~~The Company~~Our ~~has~~products, ~~lease~~broadly ~~commitments for its European operations under private companies~~described, ~~MLS~~are medical ~~Lap~~cannabinoid ~~B.V.~~formulations ~~and~~developed ~~MJR~~from ~~B.V.~~one ~~owned~~or ~~and~~more ~~controlled by Mario Lap, director~~ of the ~~Company~~cannabinoid ~~and~~compounds ~~director~~found ~~and~~in ~~officer~~the ofcannabis ~~EU subsidiaries~~plant. ~~Negotiations~~Our ~~are~~immediate focus ~~ongoing~~is ~~in regards~~ to ~~preparing finalized~~treat ~~agreements~~one ~~between~~of the ~~Company~~most ~~and~~important ~~Mr.~~diseases ~~Lap’s~~in ~~companies~~the world, cancer.

FCS-15S/BCC1 is in preparation to enter phase I clinical trials within one to two year. This product is formulated for topical administration to be tested in phase I study, with an indication for skin cancer.

~~12. SUBSEQUENT EVENTS~~4

OnCS-TATI1 is in preclinical development ~~October~~with 9,the ~~2016,~~indication for infectious disease. Consistent with data published in March by researchers at the ~~Company~~Mount ~~entered~~Sinai aSchool of ~~Consulting~~Medicine ~~Management~~found ~~Agreement~~that ~~for~~cannabinoids ~~services~~inhibit ~~and~~TAT induced migration to ~~issue~~TAT ~~1,000,000~~via ~~shares~~cannabinoid of2 ~~Rule~~receptors ~~144 restrict~~(CB2) ~~common~~which ~~stock~~has ~~with~~potential applications ain ~~fair~~HIV ~~market~~and ~~value~~other ofinfectious ~~$21,500~~diseases.

~~On October~~In ~~24,~~November ~~2016~~2013, ~~the~~Cannabis ~~Company~~Science ~~entered~~submitted patent anapplication ~~Exclusive~~N2010968 ~~Master~~in ~~Facilitator~~Europe ~~Agreement~~entitled ~~with~~"Composition ~~Members~~for ofthe ~~Winnemucca~~Treatment ~~Tribal~~of ~~Allotment,~~Neurobehavioral ~~Free~~Disorders." The ~~Spirit~~subject ~~Organics,~~of ~~LLC,~~the ~~American~~patent ~~Education~~is ~~Consulting~~development ~~Group~~of ~~and~~cannabinoid-based ~~Raymond~~formulations ~~C. Dabney University~~ to ~~provide~~treat ~~general~~a ~~support~~variety ~~with developing, cultivating and processing~~ of ~~Cannabis/Hemp~~neurobehavioral ondisorders, ~~320~~such ~~Acres~~as attention ofdeficit ~~leased~~hyperactivity ~~land~~disorder in(ADHD) ~~Humboldt~~and ~~County, Nevada~~anxiety. The ~~Company’s~~first ~~share is~~formulation ~~40%~~in ~~of net profit derived from~~ the ~~sale~~series ~~and distribution~~ of ~~Cannabis/Hemp~~neurobehavioral disorder-targeted products ~~grown~~is ~~and~~the ~~manufactured~~pre-clinical ondevelopment ~~these~~and ~~lands.~~use ~~Under the~~of ~~agreement,~~ the ~~Company~~invention ~~will~~in befood ~~provided~~products ~~one~~through ~~(1)~~a ~~acre~~licensing ofagreement ~~land~~with ~~for~~a ~~research~~strategic partner and ~~development~~related ~~with~~company, ~~placement~~OmniCanna ofHealth ~~no more than 36~~Solutions,~~000 square~~ ~~feet~~Inc. ofAnd ~~greenhouses~~Cannabis ~~used~~Science ~~for~~will ~~cultivation~~move ~~and~~forward ~~research~~at ofthe ~~Cannabis/Hemp.~~same ~~The~~time ~~term~~with ~~of this Exclusive Master Agreement is~~pharmaceutical ~~five~~grade ~~(5)~~product ~~years and up to twenty-five (25) years~~development.

~~F-16~~Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.

~~PART~~To date hundreds of natural constituents Icovering several chemical classes have been isolated and identified from the Cannabis plant.

~~CAUTIONARY STATEMENT~~Some ~~REGARDING~~key ~~FORWARD-LOOKING~~phytocannabinoids ~~INFORMATION~~are:

~~This Interim~~· ~~Report~~etrahydrocannabinol on Form 10-Q contains forward-looking statements that have been made pursuant to the provisions of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from historical results or from those projected in the forward-looking statements. Discussions containing forward-looking statements may be found in the material set forth under “Business,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in other sections of this Form 10-Q. Words such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable as of the date of this Report, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Interim Report on Form 10-Q. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations.(THC)

~~Readers should~~· ~~carefully~~cannabidiol review and consider the various disclosures made by us in this Report, set forth in detail in Part I, under the heading “Risk Factors,” as well as those additional risks described in other documents we file from time to time with the Securities and Exchange Commission, which attempt to advise interested parties of the risks, uncertainties, and other factors that affect our business. We undertake no obligation to publicly release the results of any revisions to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.(CBD)

~~ITEM 2. MANAGEMENT’S~~· ~~DISCUSSION~~cannabigerol ~~AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~(CBG)

~~This section~~· ofcannabichromene this report includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements, which apply only as of the date of this report. These forward-looking states are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or our predictions.(CBC)

~~Overview of~~· ~~the~~cannabinol ~~Company’s Business~~(CBN)

~~Cannabis Science,~~These ~~Inc.~~cannabinoids ~~(formerly~~belong ~~Gulf~~to ~~Onshore, Inc.) (“We” or “~~the ~~Company”), was incorporated under~~chemical ~~the~~class ~~laws~~ of ~~the~~terpenophenolics, ~~State~~ of ~~Colorado,~~which on85 ~~February~~have ~~29,~~been ~~1996,~~uniquely asidentified ~~Patriot~~in ~~Holdings~~cannabis, ~~Inc. On~~including ~~August 26, 1999,~~ the ~~Company changed~~most ~~its~~psychoactive ~~name to National Healthcare Technology~~cannabinoid, ~~Inc. On June 6, 2007, the Company changed its name from National Healthcare~~ ~~Technology, Inc~~THC., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc.

~~Cannabis Science,~~Some ~~Inc.~~applications ~~is at the forefront~~ of ~~medical~~cannabinoids ~~cannabis~~have been ~~research~~well ~~and~~established ~~development. The~~in ~~Company~~peer-reviewed ~~works~~literature ~~with~~such ~~world~~as ~~authorities on~~for ~~phytocannabinoid~~alleviating ~~science~~nausea ~~targeting critical illnesses,~~ and ~~adheres~~stimulating tothe ~~scientific~~appetite ~~methodologies~~for topeople ~~develop,~~with ~~produce,~~ AIDS and ~~commercialize phytocannabinoid-based pharmaceutical products~~cancer. In ~~summary,~~Other ~~we are dedicated to the creation of cannabis~~well-~~based~~known ~~medicines, both~~uses ~~with~~include ~~and~~easing ~~without~~chronic ~~psychoactive~~pain ~~properties, to treat disease~~ and ~~the~~reducing ~~symptoms~~muscle ofspasms ~~disease,~~associated aswith ~~well~~multiple assclerosis ~~for~~and spinal ~~general~~cord ~~health maintenance~~injuries.

~~Cannabis Science,~~The ~~Inc.,~~pharmacology ~~takes advantage~~ of ~~its~~THC ~~unique~~has ~~understanding~~been ~~of metabolic processes to provide novel treatment approaches to a number~~widely ofstudied, ~~illnesses~~while ~~for~~many ~~which~~other ~~current~~identified ~~treatments~~cannabinoids ~~and~~are ~~understanding~~still ~~remain~~poorly ~~unsatisfactory. The~~characterized ~~Company~~pharmacologically ~~works with leading experts in drug development, medicinal characterization,~~ and ~~clinical research to develop~~biologically, ~~produce,~~with ~~and~~new ~~commercialize novel therapeutic~~activities ~~approaches~~ for ~~the~~cannabinoids ~~treatment~~consistently ~~for~~being ~~illnesses caused by infections as well as for age-related illness~~discovered. ~~Our initial focus is on skin cancers and neurological conditions.~~

Cannabis Science, ~~Inc~~is developing novel cannabis based approaches to treat the world’s most deadly illnesses. ~~takes~~We ~~advantage~~learn offrom ~~its~~patients ~~unique~~about ~~understanding~~the healing properties of ~~metabolic~~cannabis ~~processes~~medicines. toOur ~~provide~~immediate ~~innovative~~focus ~~treatment~~is ~~options~~the ~~for~~development ~~unmet medical~~of ~~needs~~cutting edge cancer treatments.

3The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.

~~Cannabis use~~The ~~has~~endocannabinoid ansystem ~~extensive~~possessed by ~~history~~all ~~dating~~vertebrates ~~back~~regulates ~~thousands~~all ofbody ~~years,~~systems and ~~currently~~maintains ~~there~~homeostasis. ~~are~~As ~~thousands~~such, ~~of peer-reviewed scientific publications that document~~ the ~~underlying~~mechanisms ~~biochemical~~of ~~pathways~~phytocannabinoids’ ~~that~~biological impact ~~cannabinoids~~are ~~modulate~~multidimensional.

~~We are~~While ~~dedicated~~concentrating toon ~~working~~our ~~closely~~core ~~with~~activities of ~~local,~~discovering ~~national~~ and ~~international~~developing ~~regulatory~~treatments ~~agencies~~that towill ~~provide~~make ~~access~~a tomeaningful ~~high~~difference ~~quality~~in patients’ lives, we remain mindful that ~~first~~we ~~class~~have ~~cannabinoid~~other ~~pharmaceuticals~~responsibilities to ~~those~~the ~~critically~~clinicians inwho ~~need~~utilize ofour ~~new~~drugs, ~~treatments~~health ~~for~~authorities ~~life~~around ~~threatening~~the ~~and~~world, ~~debilitating~~our ~~conditions.~~shareholders, ~~Cannabis~~our ~~Science’s~~employees, ~~clinical~~and ~~trial~~the ~~material~~communities ~~comes~~in ~~from~~which ~~the~~we ~~cultivation~~live and ~~production~~work. We ~~facilities~~continually ~~that~~strive ~~are~~to ~~GMP~~improve ~~compliant,~~our corporate responsibility ~~surpassing~~standards ~~high~~and ~~quality~~activities, ~~standard~~implementing ~~industrial~~comprehensive ethical standards and ~~food~~undertaking ~~processing~~patient ~~requirements~~and community progressive initiatives.

~~The Company~~These ~~works~~principles ~~with~~reflect ~~leading~~the ~~experts~~mission of inCannabis ~~drug~~Science ~~development, medicinal characterization, and clinical research~~ to ~~develop,~~provide ~~produce, and~~innovative ~~commercialize~~therapeutics ~~novel therapeutic approaches~~ for ~~the~~unmet ~~treatment~~medical ~~of multiple critical ailments from cancer and infections to age-related illnesses~~needs.

~~Our products,~~As ~~broadly~~the ~~described~~industry leader, ~~are~~Cannabis ~~medical~~Science consults ~~cannabinoid~~and ~~formulations~~leads ~~developed~~other ~~from~~emerging ~~one~~businesses orthat ~~more~~Cannabis ofScience ~~the~~believes ~~cannabinoid~~has ~~compounds~~a ~~found~~preferred business model, one which will mature into a key business model in the ~~cannabis plant~~future. Our ~~immediate~~consulting ~~focus~~ is toon ~~treat~~the ~~one~~entire of"seed ~~the~~to ~~most~~sale" ~~important~~process ~~diseases~~with ina ~~the~~focus ~~world,~~on ~~cancer~~bio-pharmaceutical development.

~~CS-S/BCC1~~ Cannabis Science is one of the longest standing companies in ~~preparation~~the tocannabis ~~enter~~business. We ~~phase~~feel Ithat ~~clinical~~the ~~trials~~correct ~~within~~way ~~one~~is to ~~two~~look ~~year.~~at ~~This~~the ~~product~~industry isfrom ~~formulated~~a ~~for~~bio-pharmaceutical standpoint, ~~topical~~in ~~administration to~~a bemanner ~~tested~~that inallows ~~phase~~cannabinoid-based Iproducts ~~study,~~to ~~with~~modulate anthe ~~indication~~endocannabinoid ~~for~~system ~~skin~~to ~~cancer~~treat multiple conditions.

~~CS-TATI1 is~~On inMarch ~~preclinical~~30, ~~development~~2009, the Company entered into an agreement with ~~the~~Cannex ~~indication~~Therapeutics, ~~for~~LLC, ~~infectious~~(“Cannex”) ~~disease~~a California limited liability company, and its principal, medical cannabis pioneer and entrepreneur Steven W. ~~Consistent~~ ~~with~~Kubby, ~~data~~to ~~published~~acquire all of their interest in ~~March~~certain byassets ~~researchers~~used to conduct a atcannabis research and development business. The asset purchase agreement includes all of Cannex’s and Kubby’s intellectual property rights, formulas, patents, trademarks, client base, hardware and software, including the ~~Mount~~website ~~Sinai~~www.phytiva.com. The Company ~~School~~and its largest shareholder, K & D Equities, Inc., exchanged a total of ~~Medicine~~10,600,000 ~~found~~shares ~~that~~of ~~cannabinoids~~common ~~inhibit~~stock ~~TAT~~for ~~induced~~the ~~migration~~assets of toCannex; ~~TAT~~the ~~via~~Company ~~cannabinoid~~issued 2,100,000 ~~receptors (CB2)~~shares ~~which~~to ~~has~~Cannex, ~~potential~~and ~~applications~~K in& ~~HIV~~D transferred 8,500,000 shares to Cannex and ~~other~~others. A Form ~~infectious~~8-K ~~diseases~~reflecting this transaction was timely filed.

~~In November~~As ~~2013,~~part ~~Cannabis~~of ~~Science~~the ~~submitted~~Agreement, ~~patent~~on ~~application~~April ~~N2010968~~1, 2009, inthe ~~Europe~~Company ~~entitled~~appointed ~~"Composition~~Mr. ~~for~~Kubby ~~the~~as ~~Treatment~~President ~~of Neurobehavioral~~and ~~Disorders." The~~CEO, ~~subject~~Richard ofCowan ~~the~~as ~~patent~~Director isand ~~development~~CFO, ofand ~~cannabinoid-based~~Robert ~~formulations~~Melamede toPh. ~~treat~~D., aas ~~variety~~Director ofand ~~neurobehavioral~~Chief ~~disorders,~~Science ~~such~~Officer. Each asof ~~attention~~them ~~deficit~~was ~~hyperactivity~~also ~~disorder~~appointed ~~(ADHD)~~as ~~and~~a ~~anxiety~~director. All ~~The~~of ~~first~~the ~~formulation~~Company’s incurrent ~~the~~directors ~~series~~then ofresigned. On ~~neurobehavioral~~April ~~disorder-targeted~~7, ~~products~~2010, is the ~~pre-clinical~~Company ~~development~~changed ~~and~~its ~~use~~name ofto ~~the~~Cannabis ~~invention~~Science, inInc., ~~food~~and ~~products through~~obtained a ~~licensing~~new ~~agreement~~CUSIP ~~with~~number. Its shares anow ~~strategic~~trade ~~partner~~under ~~and~~the ~~related~~symbol ~~company,~~CBIS.OB. A ~~OmniCanna~~Form ~~Health~~8-K ~~Solutions~~was timely filed, ~~Inc.~~with ~~And~~a ~~Cannabis~~copy ~~Science will~~of ~~move~~the ~~forward~~Asset atAcquisition ~~the~~Agreement and ~~same~~Board ~~time~~Resolution ~~with~~ratifying ~~pharmaceutical~~the ~~grade~~Agreement ~~product~~provided ~~development~~as exhibits thereto.

~~Cannabis~~On April 7, 2009, the Company changed ~~plants~~its ~~have~~name ~~extensive~~to ~~history~~Cannabis Science, Inc., reflecting its new business mission: Cannabis Science, Inc. is at the forefront of medical marijuana research and ~~agricultural~~development. The ~~use~~Company ~~dating~~works ~~back~~with ~~thousands~~world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of ~~years~~cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company obtained a new CUSIP number as well. Cannabis Science Inc. has also launched its new website www.cannabisscience.com reflecting its new name.

~~To date~~On ~~hundreds~~May of7, ~~natural~~2009, ~~constituents~~the ~~covering~~Company ~~several~~common ~~chemical~~shares commenced ~~classes~~trading ~~have~~under ~~been~~the ~~isolated~~new ~~and~~stock ~~identified~~symbol ~~from~~OTC: ~~the Cannabis plant~~CBIS.

~~Some~~The Company formed two operating subsidiaries Cannabis Science ~~key~~BV ~~phytocannabinoids~~and ~~are:~~Cannabis Science International Holding BV in The Netherlands on May 10th and May 6th , 2013, respectively, to pursue business opportunities in Europe and worldwide.

•There ~~tetrahydrocannabinol~~are ~~(THC)~~minimal operating activities in the subsidiaries as of March 31, 2017,. Mario Lap, a director of the Company and director and officer its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MLS Lap B.V., MJR B.V. and Cannabis Agency B.V. until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time.

~~• cannabidiol (CBD)~~6

•On ~~cannabigerol~~August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (~~CBG~~“MGT”) to acquire an additional 30.1% equity in MGT that would increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company issued a total of twenty million (20,000,000) shares to the principals and shareholders of MGT over 12 months (see Form 8-K with the SEC on file no. 000-28911 August 8, 2014).

•On ~~cannabichromene~~January 5, 2015 the Company announced the International release of 8 initial products that will be synergistically produced, distributed and marketed across the Netherlands, Spain and California where Cannabis Science is active and has cannabis production facilities. The products are currently ready for pre-clinical studies, self-medicating patient ailment usage, marketing release, sales and distribution. The company also released The Cannabis Science Patient Access Center (~~CBC~~PAC) http://pac.cannabisscience.com, in beta version, is now available for patients to track usage and receive updates.

•On ~~cannabinol~~May 7, 2015 the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (~~CBN~~10,000,000) shares to the shareholders of Equi-Pharm and agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. The Company is working closely with management of Equi-Pharm to expand the product lines.

~~These cannabinoids~~On ~~belong~~May to19, ~~the~~2015 ~~chemical~~Cannabis ~~class~~Science ofannounced ~~terpenophenolics,~~the expansion of ~~which~~licensing 85deal ~~have~~with ~~been~~Purple ~~uniquely~~Haze ~~identified~~Properties. inCannabis Science and Purple Haze Properties are working together to launch exciting lines of quality cannabis, ~~including~~products using scientific genetics and creating an education platform to share information from doctors and patients around the ~~most~~world ~~psychoactive~~about ~~cannabinoid,~~the ~~THC~~advances of cannabis research.

~~Some~~On May 27, 2015 the Company announced a Historic Collaborative ~~applications~~Drug ofDevelopment ~~cannabinoids~~deal ~~have~~with ~~been~~IGXBio ~~well~~and ~~established~~its inGenePro®, ~~peer~~a DNA-~~reviewed~~based ~~literature~~immunotherapeutic ~~such~~that asrecently ~~for~~received ~~alleviating~~FDA ~~nausea~~IND ~~and~~approval ~~stimulating~~to ~~the~~enter ~~appetite~~into ~~for~~human ~~people~~trials. ~~with~~The ~~AIDS~~companies ~~and~~intend ~~cancer.~~to ~~Other~~develop a joint protocol to demonstrate potential synergistic effects of their respective drug candidates in HIV, as well~~-known~~ ~~uses~~as ~~include~~potential ~~easing~~new ~~chronic~~drug ~~pain~~candidates. ~~and~~IGXBio ~~reducing~~is ~~muscle~~a ~~spasms~~privately ~~associated~~held clinical stage biotechnology ~~with~~company ~~multiple~~developing ~~sclerosis~~advanced ~~and~~DNA ~~spinal~~immunotherapies ~~cord~~for ~~injuries~~HIV infection, based in Fairway, KS, USA.

4On July 16, 2015 Cannabis Science announced guidance in regards to its State-by-State initiatives, including its new product releases. On the forefront are the California new product releases. The Company has signed a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF will be responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives in California. The CSRF distribution agreement is due to the committed focus CBIS has on its federal drug development program. As a result of this new agreement with CSRF the Cannabis Science Patient Access Center will be moved to the CSRF website as well.

~~The~~On November 2, 2015, the Company announced a significant ~~pharmacology~~collaborative drug development deal with IGXBio Inc., and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies developed joint protocols that explore potential synergistic effects of ~~THC~~their respective drug candidates, as well as potential new drug candidate opportunities. IGXBio has ~~been~~a ~~widely~~drug ~~studied~~called GenePro®, which ~~while~~is ~~many~~already ~~other~~registered ~~identified~~with ~~cannabinoids~~the FDA and has an IND number. This expedites the process to seek FDA approval in the future. GenePro® is designed to promote an anti-HIV immune response that facilitates virus control in HIV-infected subjects. There are ~~still~~more ~~poorly~~than ~~characterized~~150 ~~pharmacologically~~peer-reviewed publications that describe the effectiveness of GenePro®. The inflammatory response that is ~~and~~associated ~~biologically~~with HIV infection is present at even low levels of viral replication, ~~with~~and ~~new~~is ~~activities~~a major causal factor for ~~cannabinoids~~the ~~consistently~~morbidities and ~~being~~associated ~~discovered~~mortality of HIV infection. Low-grade inflammation frequently occurs despite clinically successful anti-retroviral therapy and is associated with increased incidence of heart disease, bone disease, and cancers.

~~Cannabis Science~~On isNovember ~~developing~~11, ~~novel~~2015, ~~cannabis~~Cannabis ~~based~~Science ~~approaches~~announced ~~to treat~~ the ~~world’s most deadly illnesses. We learn from patients~~release ~~about the healing properties~~ of ~~cannabis~~seven ~~medicines.~~original ~~Our~~cannabinoid-based ~~immediate~~animal ~~focus~~care isproducts ~~the~~through ~~development~~its ofwholly ~~cutting~~owned ~~edge~~subsidiary, ~~cancer~~Equi-Pharm, ~~treatments~~LLC.

The Company’s future endeavors include infectious illnesses, neurobehavioral disorders including attention deficit disorder, post-traumatic stress disorder; and an application of the anti-inflammatory activities of cannabis in the management of age-related illnesses.7

~~The~~On November 25, 2015, the Company announced positive results ~~endocannabinoid~~from ~~system~~its ~~possessed~~initial bytest ~~all~~run ~~vertebrates~~of ~~regulates~~its ~~all~~Pure ~~body~~Decarboxylated ~~systems~~CO2 Oil (PDCO) released through the Cannabis Science Research Foundation (CSRF or the Foundation) to 15 dispensaries and ~~maintains~~several ~~homeostasis~~less fortunate self-medicating patients. AsThis ~~such~~trial, collaborative rollout by CSRF, as contracted by Cannabis Science to the ~~mechanisms~~California not-for-profit, was designed to meet two primary goals. The first, to conduct tests on the efficacy of ~~phytocannabinoids’~~the ~~biological~~product ~~impact~~for patients; the second, to gather proprietary data based on testimonials from real self-medicating consumers from their firsthand experiences. The feedback received will be used to influence the Company's continuing efforts to bring the best cannabinoid-based formulations to market On November 30, 2015 Cannabis Science announced the launch of their cannabinoid-formulated capsule product line. The initial capsule formulations released are ~~multidimensional~~CBD, Indica, and Sativa; each of the three types of caps will be available in 25mg, 50mg, and 100mg doses and will be provided in two-dose packs with more size options to be made available in the near future.

~~While concentrating~~On onDecember ~~our~~10, ~~core~~2015, ~~activities~~the ofCompany ~~discovering~~announced ~~and developing treatments~~ that ~~will make a meaningful difference in patients’~~Cannabis ~~lives,~~Science weentered ~~remain mindful that we have other responsibilities to the clinicians who utilize our drugs~~Select, ~~health~~New ~~authorities~~High-Dosage ~~around the~~product ~~world,~~line ~~our~~of ~~shareholders~~CBD, ~~our employees~~Sativa, and ~~the~~Indica ~~communities~~Capsules ininto ~~which~~the weIndustry-Famous ~~live~~Emerald ~~and~~Cup ~~work. We continually strive to improve~~Event ~~our~~in ~~corporate~~Santa ~~responsibility standards and activities~~Rosa, ~~implementing~~CA ~~comprehensive~~on ~~ethical~~December ~~standards~~12th and ~~undertaking patient and community progressive initiatives~~13th.

~~These~~On December 15, 2015 after successful formulation ~~principles~~work, ~~reflect~~Cannabis Science follows through with a full clinical drug development agreement with ImmunoClin to deliver GMP quality pre-clinical data to enter CS-NEURO-1 into a Phase I human study in Europe. After ImmunoClin successfully completed its one-year formulation work for CBIS, focusing on cannabis extracts and cannabinoids, the ~~mission~~results are compelling and conclusive. ImmunoClin will, under its class I license, initiate, manage, and coordinate all aspects of the new comprehensive clinical research program on behalf of Cannabis Science. The new program will focus on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to ~~provide~~enable ~~innovative~~entry ~~therapeutics~~of ~~for~~CS-NEURO-1 ~~unmet~~and ~~medical~~other ~~needs~~cannabinoid based products into a Phase I human studies in Europe.

AsOn March 24, 2016, the Company entered a 15 years Joint Venture License Agreement with the Ft. ~~industry~~McDermitt ~~leader~~Allotment land Allotees, ~~Cannabis~~which ~~Science~~is ~~consults~~on ~~and~~the ~~leads~~Ft. ~~other~~McDermitt ~~emerging~~Tribal ~~businesses~~Reservation, ~~that~~Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, ~~believes~~Inc. ~~has~~for a ~~preferred~~total of ten (10), one (1) acre parcels ~~business~~of ~~model~~land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made an initial payment of $50,000 for farming rights and initial development of the first two one ~~which~~(1) ~~will~~acre ~~mature~~parcel ~~into~~of aland located ~~key~~in ~~business~~Fort ~~model~~McDermitt Tribal Reservation in the ~~future~~State of Nevada, USA. Each ~~Our~~one ~~consulting~~(1) acre parcel of land is onspecifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the ~~entire~~production ~~"seed~~of Cannabis and all Cannabis related products. All harvested products are to ~~sale"~~be delivered and sold to qualified licensed distribution centers. ~~process~~The ~~with~~Company ais ~~focus~~to onshare ~~bio-pharmaceutical~~40% ~~development~~of the Adjust Gross Income after deduction of related operating expenses and cost to build the green houses.

On October 24, 2016, the Company entered an Exclusive Master Facilitator Agreement with Members of Winnemucca Tribal Allotment, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing of Cannabis/Hemp ~~Science~~on 320 Acres of leased land in Humboldt County, Nevada. The Company’s share is ~~one~~40% of net profit derived from the ~~longest~~sale ~~standing~~and distribution ~~companies~~of inCannabis/Hemp products grown and manufactured on these lands. Under the ~~cannabis~~agreement, ~~business~~the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is five (5) years and up to twenty-five (25) years.

WeOn November 12, 2016, the Company entered ~~feel~~an ~~that~~Exclusive Master Facilitator Agreement with the ~~correct~~Members ~~way~~of isWashoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to ~~look~~provide atgeneral ~~the~~support ~~industry~~with developing, ~~from~~cultivating aand ~~bio-pharmaceutical~~processing ~~standpoint~~Cannabis/Hemp with Free Spirit Organics, LLC on Lot 20, one (1) acre parcel of leased land located in the allotment cc183, a ~~manner~~portion ~~that~~of ~~allows~~the ~~cannabinoid~~SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Company’s share is 20% on all initial non-~~based~~refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products togrown ~~modulate~~and manufactured on the ~~endocannabinoid~~land. ~~system~~Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years. On December 21, 2016, the Company paid $40,000 to ~~treat~~the ~~multiple~~property ~~conditions~~owner under the agreement for the one (1) acre of land.

On March 30, 2009, the Company entered into an agreement with Cannex Therapeutics, LLC, (“Cannex”) a California limited liability company, and its principal, medical cannabis pioneer and entrepreneur Steven W. Kubby, to acquire all of their interest in certain assets used to conduct a cannabis research and development business. The asset purchase agreement includes all of Cannex’s and Kubby’s intellectual property rights, formulas, patents, trademarks, client base, hardware and software, including the website www.phytiva.com. The Company and its largest shareholder, K & D Equities, Inc., exchanged a total of 10,600,000 shares of common stock for the assets of Cannex; the Company issued 2,100,000 shares to Cannex, and K & D transferred 8~~,500,000 shares to Cannex and others. A Form 8-K reflecting this transaction was timely filed.~~

AsOn December 18, 2016, the Company enter ~~part~~six (6) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the ~~Agreement~~Members of Washoe Tribal Allotments in Douglas County, onNevada, ~~April~~together 1with Free Spirit Organics, ~~2009~~LLC, ~~the~~American ~~Company~~Education ~~appointed~~Consulting MrGroup and Raymond C. ~~Kubby~~Dabney asUniversity to ~~President~~provide ~~and~~general ~~CEO~~support with developing, ~~Richard~~cultivating ~~Cowan~~and asprocessing ~~Director~~Cannabis/Hemp ~~and~~with ~~CFO~~Free Spirit Organics, LLC on 13 one (1) ~~and~~acre ~~Robert~~parcel ~~Melamede~~of ~~Ph.~~leased D.land, asLot ~~Director~~1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and ~~Chief~~14, ~~Science~~located ~~Officer. Each~~in the allotment cc183, a portion of ~~them~~the SE ~~was~~¼ ~~also~~of ~~appointed~~section as15, atownship ~~director~~11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. ~~All~~ The Family Allotment ofwill ~~the~~receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s ~~current~~share ~~directors~~is ~~then~~20% ~~resigned. On~~on ~~April~~all 7,initial non-refundable ~~2010~~deposits from external investor, ~~the~~and ~~Company~~10% ~~changed~~of ~~its~~net ~~name~~profit toderived from the sale and distribution of Cannabis/Hemp products ~~Science,~~grown ~~Inc~~and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and ~~obtained~~development with aplacement ~~new~~of ~~CUSIP~~no ~~number. Its~~more ~~shares~~than ~~now~~36,000 ~~trade~~square ~~under~~feet ~~the~~of ~~symbol~~greenhouses ~~CBIS~~used for cultivation and research of Cannabis/Hemp.~~OB. A~~ ~~Form~~The ~~8-K~~term of ~~was~~this ~~timely~~Exclusive ~~filed~~Master Agreement is twenty-five (25) years renewable every five (5) years. On December 23, ~~with~~2016, athe ~~copy~~Company ofpaid $100,000 to the ~~Asset~~property ~~Acquisition~~owner ~~Agreement~~members ~~and~~under ~~Board~~the ~~Resolution~~agreements ~~ratifying~~and record the ~~Agreement~~unpaid ~~provided~~balance asof ~~exhibits thereto~~$420,000 in accounts payable.

On ~~April~~ 7December 21, ~~2009~~2016, the Company enter ~~changed~~two ~~its~~(2) ~~name~~Exclusive toMaster ~~Cannabis~~Facilitator ~~Science~~Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, ~~Inc.~~Nevada, ~~reflecting~~together ~~its~~with ~~new~~Free ~~business~~Spirit ~~mission:~~Organics, ~~Cannabis Science~~LLC, American Education Consulting Group and ~~Inc~~Raymond C. isDabney atUniversity ~~the~~to ~~forefront~~provide ofgeneral ~~medical~~support ~~marijuana~~with ~~research~~developing, cultivating and ~~development. The~~processing ~~Company~~Cannabis/Hemp ~~works~~ with ~~world~~Free Spirit ~~authorities~~Organics, LLC on ~~phytocannabinoid science~~two ~~targeting~~(2) ~~critical~~one ~~illnesses~~(1) acre parcel of leased land, Lot 6 and ~~adheres~~21, tolocated ~~scientific~~in ~~methodologies~~the toallotment ~~develop~~cc183, ~~produce~~a portion of the SE ¼ of section 15, ~~and~~township ~~commercialize~~11 ~~phytocannabinoid-based~~North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The ~~pharmaceutical~~Family ~~products~~Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. In ~~sum~~The Company’s share is 20% on all initial non-refundable deposits from external investor, weand ~~are~~10% ~~dedicated~~of tonet profit derived from the ~~creation~~sale and distribution of ~~cannabis-based~~Cannabis/Hemp ~~medicines~~products grown and manufactured on the land. Under the agreement, ~~both~~the ~~with~~Company ~~and~~will ~~without~~be ~~psychoactive~~provided ~~properties,~~one to(1) ~~treat~~acre ~~disease~~of land for research and ~~the~~development ~~symptoms~~with placement of ~~disease~~no more than 36,000 assquare ~~well~~feet asof greenhouses used for cultivation ~~general~~and ~~health~~research ~~maintenance~~of Cannabis/Hemp. The ~~Company~~term ~~obtained a~~of ~~new~~this ~~CUSIP~~Exclusive ~~number~~Master asAgreement ~~well. Cannabis~~is ~~Science~~twenty-five ~~Inc~~(25) years renewable every five (5) years. ~~has~~On ~~also~~December ~~launched~~23, ~~its~~2016, ~~new~~the ~~website~~Company ~~www.cannabisscience.com~~paid ~~reflecting~~a ~~its~~total of $45,000 to the two property owners under the ~~new~~agreements ~~name~~and recorded the unpaid balance of $35,000 in accounts payable.

On ~~May~~ 7January 3, ~~2009~~2017, the Company ~~common~~entered a ~~shares~~Research ~~commenced~~Collaboration ~~trading~~Agreement ~~under~~with Dana-Farber Cancer Institute, Inc. of Boston Massachusetts for a research project to develop and investigate the ~~new~~use ~~stock~~of ~~symbol~~Cannabinolds ~~OTC:~~to ~~CBIS~~cure various caner, and investigate synergies with radiotherapy and immunotherapy. In consideration for this Agreement and performance of the Research, the Company has paid $201,656 to Dana-Farber Cancer Institute, Inc.

5On February 2, 2017, the Cannabis Science GmbH, a subsidiary 90% owned by the Company and 10% owned by Dupetit Natural Products GmbH, has entered a Share Purchase Agreement with Jinvator BioMed GmbH (Jinvator), a German corporation, for 74.9% of the total issued and outstanding shares of Jinvator for three hundred thousand Euros (€ 300,000) which has a US dollar equivalent of $324,300. The acquisition is pending on verifications of key information.

The Company ~~formed~~is ~~two~~working ~~operating~~on ~~subsidiaries~~several ~~Cannabis~~business ~~Science~~acquisition and BVdevelopment ~~and~~projects ~~Cannabis~~to ~~Science~~increase ~~International~~business ~~Holding~~and BVrevenue generation in ~~The~~2017 ~~Netherlands on~~and ~~May~~beyond, ~~10th~~including ~~and~~but ~~May~~not ~~6th~~limited to: product licensing and royalty agreements, ~~2013~~private label hemp product line, ~~respectively~~consulting, and other strategic acquisitions to ~~pursue~~support ~~business~~product development, ~~opportunities~~production, inand ~~Europe~~distribution of newly acquire or manufactured cannabis and ~~worldwide~~hemp based products. There can be no assurance that these will be successful in generating revenues in 2017.

There are minimal operating activities in the subsidiaries as of September 30, 2016. Mario Lap, a director of the Company and director and officer its European subsidiaries, is conducting various business activities of the Company in Spain under his personal name and/or his personal holding companies MLS Lap B.V., MJR B.V. and Cannabis Agency B.V. until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time. Liquidity

OnThe Company has a working capital deficit ~~August~~of 6$4,050,319 ~~2014~~as of March 31, ~~the~~2017, ~~Company~~compared ~~signed~~to a ~~proposal~~working ~~letter~~capital ~~with~~deficit ~~Michigan~~of ~~Green Technologies~~$2,983,206 ~~LLC~~as ~~(“MGT”)~~of toDecember ~~acquire~~31, an2016, ~~additional 30.1%~~There ~~equity~~are ininsufficient liquid ~~MGT~~assets ~~that~~to ~~would~~meet ~~increase~~current ~~the~~liabilities ~~Company’s~~or ~~equity~~sustain ~~ownership~~operations tothrough ~~50.1%. As~~2016 ~~consideration~~and ~~for~~beyond ~~acquiring~~and the Company must raise additional ~~30.1%~~capital to ~~equity,~~cover the ~~Company~~working ~~issued~~capital adeficit. ~~total~~Management ofis ~~twenty~~working ~~million~~on ~~(20,000,000)~~plans ~~shares~~ to ~~the~~raise ~~principals~~additional ~~and~~capital ~~shareholders~~through ofprivate placements and ~~MGT~~lending ~~over~~facilities. The 12Company ~~months~~currently ~~(see~~is ~~Form~~relying ~~8-K~~on ~~with~~existing ~~the~~cash ~~SEC~~and onloans ~~file~~from ~~no.~~stockholders ~~000-28911~~to ~~August~~meet 8,its ~~2014)~~obligations and sustain operations.

~~On January~~The ~~5, 2015 the~~ Company ~~announced~~has ~~the~~promissory ~~International~~note ~~release~~payment commitments of ~~8 initial products that will be synergistically produced~~$1,340,156 ~~distributed and~~due ~~marketed~~to ~~across~~stockholders ~~the Netherlands, Spain~~ and ~~California~~currently ~~where Cannabis Science~~ is ~~active~~in ~~and has cannabis production facilities~~default. The ~~products~~Company ~~are~~is ~~currently~~negotiating ~~ready~~with ~~for~~the ~~pre-clinical~~debtors ~~studies,~~to extend ~~self-medicating~~the ~~patient~~notes ~~ailment~~payable. ~~usage,~~In ~~marketing release~~addition, ~~sales~~the ~~and distribution.~~Company ~~The~~has ~~company~~convertible ~~also~~promissory ~~released~~notes ~~The~~payment ~~Cannabis~~commitment ~~Science~~of ~~Patient~~$670,407 ~~Access~~to ~~Center~~Raymond ~~(PAC) http://pac~~C.~~cannabisscience.com, in beta~~ ~~version~~Dabney, isCEO/Director ~~now~~of ~~available~~the ~~for~~Company ~~patients~~and $860,790 to ~~track~~Royalty ~~usage~~Management ~~and~~Services ~~receive updates~~Corp.

On May 7, 2015 the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. The Company is working closely with management of Equi-Pharm to expand the product lines.9

~~On May~~Contractual 19, 2015 Cannabis Science announced the expansion of licensing deal with Purple Haze Properties. Cannabis Science and Purple Haze Properties are working together to launch exciting lines of quality cannabis products using scientific genetics and creating an education platform to share information from doctors and patients around the world about the advances of cannabis research.Obligations

~~On May~~The ~~27, 2015 the~~ Company ~~announced~~has avarious ~~Historic~~commitments ~~Collaborative~~under ~~Drug~~consulting ~~Development deal with IGXBio and its GenePro®~~contracts, ~~a DNA-based~~ ~~immunotherapeutic~~debt ~~that~~settlement, ~~recently~~farming ~~received~~rights ~~FDA~~agreements, ~~IND~~laboratory ~~approval~~services toagreement, ~~enter into human trials. The companies intend to develop a~~ joint ~~protocol~~ ~~to demonstrate potential synergistic effects of their respective drug candidates in HIV~~development, asand ~~well~~joint asventure ~~potential new drug candidates~~agreement. ~~IGXBio is a privately held clinical stage biotechnology company developing advanced DNA immunotherapies for HIV infection, based in Fairway, KS, USA.~~

~~On July~~Capital 16, 2015 Cannabis Science announced guidance in regards to its State-by-State initiatives, including its new product releases. On the forefront are the California new product releases. The Company has signed a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF will be responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives in California. The CSRF distribution agreement is due to the committed focus CBIS has on its federal drug development program. As a result of this new agreement with CSRF the Cannabis Science Patient Access Center will be moved to the CSRF website as well.Resources

~~On November~~The ~~2, 2015 the~~ Company ~~announced~~has aadditional ~~significant~~capital ~~collaborative~~resource requirements ~~drug~~for ~~development~~personnel, ~~deal~~supplies, ~~with~~research ~~IGXBio~~and ~~Inc.~~development, ~~and~~laboratory, ~~its~~cultivation ~~GenePro®~~equipment, a ~~DNA-based~~green ~~immunotherapeutic~~houses ~~that~~and ~~recently received FDA IND approval to enter into human trials. The companies developed joint~~scientific ~~protocols~~equipment ~~that explore potential synergistic effects~~ of ~~their~~approximately ~~respective drug candidates~~$6, ~~as well as potential new drug candidate opportunities. IGXBio has a drug called GenePro®~~000,000 ~~which~~over ~~is already registered with~~ the ~~FDA~~next ~~and~~12 ~~has an IND number~~months. These ~~This~~capital ~~expedites the~~disbursements ~~process to seek FDA approval in the future. GenePro® is designed to promote an anti-HIV immune response that facilitates virus control in HIV-infected subjects. There~~ are ~~more~~dependent ~~than~~on ~~150 peer-reviewed publications that describe the effectiveness of~~management’s ~~GenePro®.~~successful ~~The~~raising ~~inflammatory response that is associated with HIV infection is present at even low levels~~ of ~~viral~~capital ~~replication, and~~through isprivate aplacements ~~major causal factor for the morbidities~~ and/or ~~associated~~lending ~~mortality of HIV infection~~facilities. ~~Low-grade inflammation frequently occurs despite clinically successful anti-retroviral therapy and is associated with increased incidence of heart disease, bone disease, and cancers.~~

6The Company is not currently in good short-term financial standing. We anticipate that we may only generate limited revenues in the near future and we will not have enough positive internal operating cash flow until we can generate substantial revenues, which may take the next two years to fully realize. There is no assurance we will achieve profitable operations. We have historically financed our operations primarily by cash flows generated from the sale of our equity securities and through cash infusions from officers and outside investors in exchange for debt and/or common stock.

~~On November~~Results ~~11, 2015, Cannabis Science announced the release~~ of ~~seven original cannabinoid-based animal care products through its wholly owned subsidiary, Equi-Pharm, LLC.~~Operations

~~On November~~For ~~25, 2015~~ the ~~Company~~three ~~announced~~months ~~positive~~ended ~~results~~March ~~from~~31, ~~its~~2017 ~~initial test run of its Pure Decarboxylated CO2 Oil~~ (~~PDCO~~“2017”) ~~released~~ ~~through the Cannabis Science Research Foundation (CSRF or the Foundation) to 15 dispensaries and several less fortunate self-medicating patients. This trial, collaborative rollout by CSRF,~~ as ~~contracted~~compared ~~by Cannabis Science~~ to the ~~California~~prior ~~not-for-profit,~~year was designed to meet two primary goals. The first, to conduct tests on the efficacy of the product for patients; the second, to gather proprietary data based on testimonials from real self-medicating consumers from their firsthand experiences. The feedback received will be used to influence the Company's continuing efforts to bring the best cannabinoid-based formulations to market On November 30, 2015 Cannabis Science announced the launch of their cannabinoid-formulated capsule product line. The initial capsule formulations released are CBD, Indica, and Sativa; each of the three ~~types~~months ofended ~~caps~~March ~~will be available in 25mg~~31, ~~50mg,~~2016 ~~and 100mg doses and will be provided in two-dose packs with more size options to be made available in the near future.~~(“2016”):

~~On December~~The ~~10, 2015 the~~ Company ~~announced~~had ~~that Cannabis Science entered Select~~$3,733 ~~New~~in ~~High-Dosage~~revenues ~~product~~for the ~~line~~2017 ofcompared ~~CBD,~~to ~~Sativa~~$2,925 ~~and Indica~~for ~~Capsules~~2016. This ~~into~~increase ~~the~~in ~~Industry-Famous~~revenue ~~Emerald~~is ~~Cup~~due ~~Event~~to inassets ~~Santa~~acquisition ~~Rosa,~~of CAEqui-Pharm onand ~~December~~license ~~12th~~revenue from ~~and~~product ~~13th~~sales.

~~On December~~Our ~~15,~~research ~~2015~~and ~~after successful formulation work, Cannabis Science follows through with a full clinical drug~~ development ~~agreement~~expenses ~~with~~increased ~~ImmunoClin~~by to$53,943 ~~deliver GMP quality pre-clinical data~~ to ~~enter~~$216,943 ~~CS-NEURO-1 into a Phase I human study in Europe. After ImmunoClin successfully completed its one-year formulation work~~ for ~~CBIS, focusing on cannabis extracts and cannabinoids,~~ the ~~results~~three ~~are compelling~~months ~~and~~ended ~~conclusive.~~March ~~ImmunoClin will~~31, ~~under~~2017 ~~its~~compared ~~class~~to ~~I license~~$163,000 ~~initiate,~~for ~~manage, and coordinate all aspects of~~ the ~~new comprehensive~~three ~~clinical~~months ~~research~~ended ~~program on behalf of Cannabis Science. The new program will focus on delivering compliant GMP~~March ~~quality pre-clinical data~~31, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe2016.

~~On March~~Our ~~24,~~unrealized ~~2016,~~gain ~~the Company entered a 15 years Joint Venture License Agreement with the Ft. McDermitt Allotment land Allotees, which is~~ on ~~the~~equity ~~Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis~~investee ~~Science,~~decreased ~~Inc.~~by ~~for a total of ten (10)~~$16,500 ~~one (1) acre parcels of land. The project is designed~~ to ~~benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made an initial payment of~~ $5052,~~000~~500 for ~~licensing~~ ~~and initial development of~~ the ~~first~~three ~~two~~months ~~one~~ended ~~(1)~~March ~~acre parcel of land located in Fort McDermitt Tribal Reservation in the State of Nevada~~31, ~~USA. Each~~ ~~one~~2017 ~~(1)~~compared ~~acre~~to ~~parcel of land is specifically designated for placement no more than twelve (12) three (3~~$69,000) ~~square foot greenhouses~~ for the ~~production~~three ofmonths ~~Cannabis~~ended ~~and all Cannabis related products. All harvested products are to be delivered~~March ~~and~~31, ~~sold to qualified licensed distribution centers~~2016. ~~The Company is to share 40% of the Adjust Gross Income after deduction of related operating expenses and cost to build the green houses.~~

~~The Company~~Net isloss ~~working~~ on ~~several~~settlement ~~business~~of ~~acquisition~~debt ~~and development projects to increase business and revenue generation in 2016~~decreased ~~and~~by ~~beyond~~$588,645 ~~including but not limited~~ to: ~~product~~$0 ~~licensing~~for ~~and~~the ~~royalty~~three ~~agreements,~~months ~~private~~ended ~~label~~March ~~hemp product line~~31, ~~consulting, and~~2017 ~~other~~compared ~~strategic acquisitions~~ to ~~support product development~~$588,645 ~~production,~~for ~~and~~the ~~distribution~~three ofmonths ~~newly~~ended ~~acquire~~March or31, ~~manufactured cannabis and hemp based products. There can be no assurance that these will be successful in generating revenues in~~ 2016.

~~Liquidity~~General and administrative expenses increased by $1,008,816 to 3,400,505 for the three months ended March 31, 2017 compared to $2,391,689 for the three months ended March 31, 2016. This increase was due to higher share prices in the stock compensation expense pursuant to management consulting and bonus agreements.

The Company ~~has~~is a working ~~capital~~on ~~deficit~~several business ofdevelopment ~~$5,031,688~~projects asto ofgenerate ~~September 30~~revenues, ~~2016~~including: ~~compared~~investing toin athe ~~working~~cultivation ~~capital~~of ~~deficit~~leased properties with Members of the $4Washoe Tribal Allotment,~~100,603 as~~ ofWinnemucca ~~December~~Tribal 31Allotment, ~~2015.~~HRM ~~There~~Farm ~~are~~and ~~insufficient~~Free ~~liquid~~Spirit ~~assets~~Organics, toLLC ~~meet~~in ~~current~~Nevada ~~liabilities~~and orCalifornia ~~sustain~~that will ~~operations~~generate ~~through~~increased ~~2016~~license, royalty revenue, Cannabis/Hemp products sales, and other strategic acquisitions to support product ~~beyond~~development, production, and ~~the~~distribution ~~Company~~of ~~must~~newly ~~raise~~acquired ~~additional~~or ~~capital~~manufactured tocannabis ~~cover~~and ~~the~~hemp ~~working~~based ~~capital deficit~~products. The ~~Management~~Company’s drug isdevelopment ~~working~~through onits ~~plans~~laboratory services to ~~raise additional~~facilitate ~~capital~~new ~~through~~inhalation ~~private~~study ~~placements~~for asthma/COPD and ~~lending~~other ~~facilities~~respiratory conditions. ~~The~~ In addition, the Company ~~currently~~signed isan ~~relying~~agreement onwith ~~existing~~Equi-Pharm ~~cash~~for the commercialization of pet products for distribution in ~~and~~California. Notwithstanding, ~~loans~~there ~~from~~can ~~stockholders~~be tono ~~meet~~assurance ~~its~~that ~~obligations~~these ~~and~~will ~~sustain~~be ~~operations~~successful in generating revenues in 2017.

~~The Company~~ITEM ~~has promissory note payment commitments of $1,340,156 due to stockholders and currently is in default~~3. ~~The~~ ~~Company is~~QUANTITATIVE ~~negotiating~~AND ~~with~~QUALITATIVE ~~the~~DISCLOSURES ~~debtors~~ABOUT toMARKET ~~extend the notes payable. In addition, the Company has a promissory note payment commitment of $725,407 to Raymond C. Dabney, CEO/Director of the Company.~~RISK

7Not applicable.

~~Contractual Obligations~~10

~~The Company~~ITEM ~~has~~4. ~~various~~CONTROLS ~~commitments~~AND ~~under consulting contracts, debt settlement, licensing agreements, laboratory services agreement, joint development, and joint venture agreement.~~PROCEDURES

~~Capital~~Our Chief Executive Officer and Chief ~~Resources~~Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report, have concluded that, based on the evaluation of these controls and procedures, that our disclosure controls and procedures were not effective.

~~The Company~~There ~~has~~were ~~additional~~no ~~capital~~changes ~~resource~~in ~~requirements~~our ~~for~~internal controls ~~personnel,~~or ~~supplies,~~in ~~research~~other ~~and~~factors ~~development,~~during ~~laboratory,~~the ~~cultivation equipment,~~last ~~green~~fiscal ~~houses~~quarter ~~and~~covered ~~scientific~~by ~~equipment~~this ofreport ~~approximately~~that ~~$5,381,500~~have ~~over~~materially ~~the~~affected, ~~next~~or 12are ~~months. These capital disbursements~~likely ~~are~~to ~~dependent~~materially onaffect ~~management~~the Company’s ~~successful~~internal ~~raising~~controls ofover ~~capital~~financial ~~through private placements and/or lending facilities~~reporting.

~~The Company~~ PART isII ~~not~~OTHER currently in good short-term financial standing. We anticipate that we may only generate limited revenues in the near future and we will not have enough positive internal operating cash flow until we can generate substantial revenues, which may take the next two years to fully realize. There is no assurance we will achieve profitable operations. We have historically financed our operations primarily by cash flows generated from the sale of our equity securities and through cash infusions from officers and outside investors in exchange for debt and/or common stock.INFORMATION

~~Results of~~ITEM ~~Operations~~1. BUSINESS

~~For the~~CAUTIONARY ~~nine~~STATEMENT ~~months~~REGARDING ~~ended~~FORWARD-LOOKING ~~September 30, 2016 (“2016”) as compared to the prior year nine months ended September 30, 2015 (“2015”):~~INFORMATION

~~The~~This Interim Report on Form 10-Q ~~Company~~contains ~~had~~forward-looking $8statements that have been made pursuant to the provisions of Section 27A of the Securities Act of 1933,~~520in~~ ~~revenues~~Section 21E ~~for~~of the ~~2016~~Securities ~~compared~~Exchange toAct $4of 1934,~~150~~ ~~for~~and ~~2015~~the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from historical results or from those projected in the forward-looking statements. ~~This~~Discussions ~~increase~~containing forward-looking statements may be found in ~~revenue~~the material isset ~~due~~forth tounder ~~assets~~“Business,” ~~acquisition~~“Management’s Discussion and Analysis of Financial Condition and Results of ~~Equi~~Operations” and in other sections of this Form 10-~~Pharm~~Q. Words such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and ~~license~~expectations reflected ~~revenue~~in the forward-looking statements are reasonable as of the date of this Report, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from ~~product~~the ~~sales~~views and expectations set forth in this Interim Report on Form 10-Q. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations.

~~Our research~~Readers should carefully review and consider ~~development~~the ~~expenses~~various ~~decreased~~disclosures made by ~~$116~~us in this Report,~~748~~ toset ~~$265~~forth in detail in Part I,~~024~~ ~~for~~under the ~~nine~~heading ~~months~~“Risk ~~ended~~Factors,” as ~~September~~well ~~30,~~as ~~2016~~those ~~compared~~additional risks described in other documents we file from time to ~~$381~~time with the Securities and Exchange Commission,~~772~~ ~~for~~which ~~the~~attempt ~~nine~~to ~~months~~advise ~~ended~~interested ~~September~~parties 30of the risks, ~~2015~~uncertainties, and other factors that affect our business. We undertake no obligation to publicly release the results of any revisions to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

~~Loss on~~As ~~investment~~used ~~increased~~in bythis ~~$971,500~~Form ~~to $971~~10-Q,~~500~~ ~~for~~ the ~~nine~~terms "we", ~~months~~"us", ~~ended~~"our", ~~September~~“the 30Company”, ~~2016~~and ~~compared~~"Cannabis toScience" $0mean ~~for~~Cannabis ~~the nine months~~Science, ~~ended~~Inc., ~~September~~unless ~~30,~~otherwise ~~2015~~indicated.

~~Net loss~~All ondollar ~~settlement~~amounts ofrefer ~~debt decreased by $349,431~~ to ~~$4,138,645 for thenine months ended September 30, 2016 compared to $4,488,076 for the ninemonths ended September 30, 2015~~U. ~~This~~S. ~~decrease~~dollars isunless ~~due to the lesser amount of debt settlement and lower share~~otherwise ~~price of the Company’s stock relative to loss related to settling debt at a lower share price~~indicated.

General and administrative expenses decreased by $2,628,102 to $6,082,880 for the nine months ended September 30, 2016 compared to $8,710,982 for the nine months ended September 30, 2015. This decrease is due to decreased stock compensation expense pursuant to management consulting and bonus agreements.Overview

~~The~~ ~~Company~~Cannabis isScience, ~~working~~Inc. (“We” onor ~~several~~the ~~business development projects to generate revenues~~“Company”), ~~including:~~was ~~signing~~incorporated aunder ~~new~~the ~~license~~laws ~~agreement with Members~~ of the ~~Winnemucca~~State ~~Tribal~~of ~~Allotment~~Colorado, on ~~and~~February ~~Free~~29, ~~Spirit Organics~~1996, ~~LLC~~as inPatriot ~~Nevada~~Holdings, ~~that~~Inc. On ~~will~~August ~~generate increased license~~26, ~~royalty revenue~~1999, ~~Cannabis/Hemp~~the ~~products~~Company ~~sales,~~changed ~~and~~its ~~other~~name ~~strategic acquisitions~~ to ~~support~~National ~~product~~Healthcare ~~development~~Technology, ~~production, and distribution~~ ofInc. ~~newly~~On ~~acquired~~June or6, ~~manufactured~~2007, ~~cannabis~~the ~~and~~Company ~~hemp~~changed ~~based~~its ~~products. The~~name ~~Company’s~~from ~~drug~~National ~~development~~Healthcare ~~through~~Technology, ~~its~~Inc., ~~laboratory services~~ to ~~facilitate~~Brighton ~~new~~Oil ~~inhalation~~& ~~study~~Gas, ~~for~~Inc., and ~~asthma/COPD~~converted ~~and~~to ~~other~~a ~~respiratory~~Nevada ~~conditions~~corporation. InOn ~~addition~~March 25, 2008 the Company ~~signed an~~changed ~~agreement~~its ~~with~~name ~~Equi-Pharm~~to ~~for~~Gulf ~~the~~Onshore, ~~commercialization of pet products for distribution in California~~Inc. ~~Notwithstanding,~~On April ~~there~~6, ~~can~~2009, bethe noCompany ~~assurance~~changed ~~that~~its ~~these~~name ~~will~~to beCannabis ~~successful~~Science, inInc., ~~generating~~and ~~revenues~~obtained ina ~~2016~~new CUSIP number.

~~ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~11

~~Not~~On May 7, 2009 the Company’s common ~~applicable~~shares commenced trading under the new stock symbol OTCQB: CBIS.

8Currently, the Company’s common shares are trading under the OTC Pink Sheets market with symbol CBIS.

~~ITEM~~Cannabis Science, Inc. is at the forefront 4of medical marijuana research and development. ~~CONTROLS~~The ~~AND~~Company ~~PROCEDURES~~works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

~~Our Chief~~ITEM ~~Executive~~1A. ~~Officer~~RISK and Chief Financial Officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report, have concluded that, based on the evaluation of these controls and procedures, that our disclosure controls and procedures were not effective.FACTORS

~~There were~~The nofollowing ~~changes~~discussion inof ~~our~~risk ~~internal~~factors contains ~~controls~~forward-looking orstatements. inThese ~~other~~risk factors ~~during~~may ~~the~~be ~~last~~important ~~fiscal~~to ~~quarter~~understanding ~~covered~~any bystatement in this ~~report~~Form ~~that~~10-Q ~~have materially~~or ~~affected,~~elsewhere. orThe ~~are~~following ~~likely~~information toshould ~~materially~~be ~~affect~~read ~~the~~in ~~Company~~conjunction with Part II, Item 7, “Management’s Discussion ~~internal~~and ~~controls~~Analysis ~~over~~of Financial Condition and Results of Operations” and the consolidated financial ~~reporting~~statements and related notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-Q.

~~PART~~Because of the following factors, as well as IIother ~~OTHER~~factors ~~INFORMATION~~affecting the Company’s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.

~~ITEM~~The Company is subject to laws and regulations ~~1. LEGAL~~worldwide, ~~PROCEEDINGS~~changes to which could hinder the Company’s medical cannabis research and increase the Company’s costs and individually or in the aggregate adversely affect the Company’s business.

~~None~~The Company is subject to laws and regulations affecting its domestic and international operations in medical research and production of medical cannabis. These U.S. and foreign laws and regulations affect the Company’s activities including, but not limited to, areas of sales to only certain legalized regions, labor, advertising, digital content, product label, consumer protection, billing, e-commerce, promotions, quality of services, media, television, intellectual property ownership and infringement, tax, import and export requirements, foreign exchange controls and cash repatriation restrictions, environmental, health, and safety.

~~ITEM~~By way of example, laws and regulations related ~~1A. RISK~~to ~~FACTORS~~cannabis in United States is listed under Schedule 1 of the Drug Enforcement Administration (DEA) as defined under the United States Controlled Substances Act even though there are 20 states have legalized medical marijuana and eight states legalized for recreational use.

~~Not~~Compliance with these laws, regulations and similar requirements may be onerous and expensive, and they may be inconsistent from jurisdiction to jurisdiction, further increasing the cost of compliance and doing business. Any such costs, which may rise in the future as a result of changes in these laws and regulations or in their interpretation could individually or in the aggregate make the Company’s products and services less attractive to the Company’s customers, delay the introduction of new products in one or more regions, or cause the Company to change or limit its business practices. The Company has implemented policies and procedures designed to ensure compliance with applicable laws and regulations, but there can be no assurance that the Company’s employees, contractors, or agents will not violate such laws and regulations or the Company’s policies and procedures.

~~ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS~~12

~~During~~Risk related to Liquidity and Capital Resources: Although our ~~the~~financial ~~nine~~statements ~~months~~have ~~ended~~been ~~September~~prepared ~~30,~~on ~~2016~~a going concern basis, we ~~have~~must ~~issued~~raise ~~securities~~additional ~~using~~capital ~~exemptions~~before ~~available~~September ~~under~~30, ~~the~~2017 ~~Securities~~to fund ~~Act~~our ofoperations ~~1933:~~in order to continue as a going concern.

AsTurner, Stone & Company, L.L.P., our independent registered ~~set~~public ~~out~~accounting ~~below~~firm for the fiscal year ended December 31, we2016, ~~have~~has ~~issued~~included ~~securities~~an explanatory paragraph in ~~exchange~~their opinion that accompanies our audited financial statements as of and for ~~private~~the ~~placements~~year ended December 31, ~~services~~2016, indicating that our current liquidity position raises substantial doubt about our ability to continue as a going concern. If we are unable to improve our liquidity position we may not be able to continue as a going concern. The accompany consolidated financial statements do not include any adjustments that might result if we are unable to continue as a going concern and, ~~for~~therefore, ~~debt:~~be required to realize our assets and discharge our liabilities other than in the normal course of business which could cause investors to suffer the loss of all or a substantial portion of their investment.

OnWe anticipate that our principal sources of liquidity will only ~~January~~be ~~11,~~sufficient ~~2016,~~to ~~the~~fund ~~Company~~our ~~issued~~activities ~~15,500,000~~needs ~~shares~~through ofSeptember ~~R144~~30, ~~restricted~~2017. ~~common~~In ~~stock~~order to ~~Apothecary~~have ~~Genetics~~sufficient ~~Investments~~cash ~~with a~~to ~~fair~~fund ~~market~~our ~~value~~operations beyond ofSeptember ~~$181~~30,~~350~~ ~~for~~2017, ~~amendment~~we towill aneed ~~property~~to ~~license~~raise ~~agreement~~additional onequity ~~February~~or 9,debt ~~2012.~~capital ~~These~~by ~~shares~~September ~~are~~30, ~~held~~2017 in ~~escrow~~order to continue as ~~with~~a ~~the~~going ~~Company’s~~concern ~~attorney~~and ~~pending~~we tocannot ~~outcome~~provide ofany ~~the~~assurance ~~acquisition~~that ofwe ~~Northern~~will ~~California~~be ~~property~~successful in doing so.

~~On January~~Our ~~20,~~stockholders ~~2016,~~are ~~the~~subject ~~Company~~to ~~issued~~significant ~~10,000,000~~dilution ~~shares~~upon the ~~S-8~~occurrence ~~registered free-trading common stock under Option Agreement~~ of ~~2015~~ ~~Equity~~certain ~~Award~~events ~~Plan~~which ~~with~~could ~~exercise~~result ~~price~~in ~~at $0.01 and~~ a ~~fair~~decrease ~~market~~in ~~value~~our ofstock ~~$117,000 to a consultant~~price.

~~On February~~As 1of December 31, 2016, ~~the~~we ~~Company~~had ~~entered~~approximately a1.53 ~~management~~billion shares ~~agreement~~of ~~with~~our acommon ~~consulting~~stock ~~firm~~reserved ~~and~~or ~~agreed~~designated tofor ~~issue~~future ~~15,000,000~~issuance ~~shares~~upon conversion of ~~R144~~outstanding convertible promissory notes. ~~restricted~~Further, ~~common~~we ~~stock~~may ~~with~~from atime ~~fair~~to ~~market~~time ~~value~~make ofan ~~$180,000~~offer ~~for~~to ~~investor~~our ~~relation~~debtors or consultants to exchange their outstanding debts or services for shares of our common stock. ~~The~~Any future issuance of common shares ~~were~~will ~~issued~~have a further dilutive effect on ~~April~~our 7,existing stockholders ~~2016~~and could result in a decrease in our stock prices.

~~On February~~Investment 7,in ~~2016,~~new ~~the~~business ~~Company~~strategies and ~~entered~~acquisitions ~~into~~could adisrupt ~~partial debt settlement agreement with Stacey R. Lewis to retire $45,854.71 of~~ the ~~$75,044~~ inCompany’s ~~promissory~~ongoing ~~notes~~business ~~originated on March 21, 2015~~ and ~~issued~~present ~~45,000,000~~risks ~~shares~~not oforiginally ~~common stock to partially settle the debt for a loss on settlement of $588,645~~contemplated.

~~On February~~The ~~22,~~Company ~~2016~~has invested, and in the ~~Company~~future ~~issued~~may 7invest,~~000,000~~ ~~shares~~in ~~S-8~~new ~~registered~~business ~~free-trading~~strategies ~~common~~or ~~stock~~acquisitions. ~~exercised~~Such ~~under~~endeavors ~~Option~~may ~~Agreementof~~involve significant risks and ~~the~~uncertainties, ~~2015~~including ~~Equity~~distraction ~~Award~~of ~~Plan~~management ~~with~~from ~~exercise~~current ~~price~~operations, atgreater ~~$0.01~~than ~~and~~expected aliabilities ~~fair~~and ~~market~~expenses, inadequate ~~value~~return of ~~$86~~capital,~~100~~ toand aunidentified ~~consultant~~issues ~~under~~not ~~management~~discovered ~~agreement for~~in athe ~~total~~Company’s ~~Stock~~due ~~Option~~diligence. ofThese ~~25,000,000~~new ~~common~~ventures are ~~shares~~inherently ~~with~~risky ~~fair~~and ~~market~~may ~~value~~not ofbe ~~$307,500~~successful.

~~On February~~The ~~22, 2016, the~~ Company’s ~~issued 6,500,000 shares S-8 registered free-trading common~~ stock ~~exercised under Option Agreement of 2015 Equity Award Plan with exercise~~ price atis ~~$0.01~~subject ~~and a fair market value of $79,950~~ to ~~a consultant under management agreement for a total Stock Option of 25,000,000 common shares with fair market value of $307,500~~volatility.

OnThe Company’s stock continues ~~February~~to ~~29,~~experience ~~2016~~substantial price volatility. Additionally, the Company, ~~issued~~the 25medical cannabis industry,~~000,000~~ ~~shares~~and ~~S-8~~the ~~registered~~stock ~~free--trading~~market ~~common~~as ~~stock~~a whole ~~under~~have ~~Option~~experienced ~~Agreement~~extreme ofstock ~~2016 Equity~~price ~~Award~~and ~~Plan~~volume ~~with~~fluctuations ~~exercise~~that ~~price~~have ataffected ~~$0.01~~stock ~~and~~prices ain ~~fair~~ways ~~market~~that ~~value~~may ofhave ~~$300,000~~been unrelated to athese ~~consultant~~companies’ ~~under~~operating ~~management agreement~~performance.

~~On March~~The ~~8, 2016, the~~ Company’s ~~issued~~ability ~~18,000,000 shares R144 restricted common stock~~ to ~~Raymond~~raise ~~Dabney,~~additional ~~CEO of the Company with a~~capital ~~fair~~to ~~market~~fund ~~value of $193,842 for bonus under November 5, 2014 management agreement.~~operations

9The Company is required to raise additional funds to acquire research and growing facilities, and to cover cost of operations. We intend to do so through additional public or private offerings of debt or equity securities. There are no commitment or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming or as to the terms of any such financings.

~~On March~~ITEM 8,2. ~~2016,~~LEGAL the Company issued 20,000,000 shares R144 restricted common stock to MLS Lap BV, a company controlled a director of the Company with a fair market value of $215,380 for bonus under June 24, 2013 management agreement.PROCEEDINGS

On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Chad Johnson, COO/General Council with a fair market value of $215,380 for bonus and services under November 25, 2014 agreementNone.

On March 8, 2016, the Company issued 20,000,000 shares R144 restricted common stock to Robert Kane, COO/Director of the Company with a fair market value of $215,380 for bonus and services under January 20, 2015 agreement.13

~~On March~~ITEM ~~22, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2015 Equity Plan with exercise price at $0~~3.01 ~~and~~UNREGISTERED aSALES ~~fair~~OF ~~market~~EQUITY ~~value~~SECURITIES ofAND ~~$226,500~~USE toOF ~~a consultant under management agreement.~~PROCEEDS

~~On March~~During ~~22,~~the ~~2016,~~three ~~the~~months ~~Company~~ended ~~issued~~March 31, 52017,~~000,000~~ ~~shares~~we ofhave ~~S-8~~issued ~~registered~~securities ~~free-trading~~using ~~common~~exemptions ~~stock~~available under ~~Option~~the ~~Agreement~~Securities ofAct ~~2016 Equity Plan with exercise price at $0.01 and a fair market value~~ of ~~$75,500 to a consultant under management agreement.~~1933:

~~On March~~As ~~22,~~set ~~2016~~out below, ~~the~~we ~~Company~~have issued ~~10,000,000~~securities ~~shares~~in ~~of S-8 registered free-trading common stock under Option Agreement of 2016~~exchange ~~Equity~~for ~~Plan with exercise price at $0.01 and a fair market value of $151,000 to a consultant under management agreement.~~services:

On ~~March~~ 22February 16, ~~2016~~2017, the Company issued 15 5,000,000 shares of ~~S-8~~R144 ~~registered~~restricted ~~free-trading~~ common stock ~~under~~to ~~Option~~a ~~Agreement~~consultant ~~of 2016 Equity Plan~~ with ~~exercise price at $0.01 and~~ a fair market value of $~~226~~350,~~500~~000 tofor alegal ~~consultant~~and general consulting services under ~~management~~a consulting agreement dated January 13, 2017.

On ~~March~~ 22February 16, ~~2016~~2017, the Company issued 10,000,000 shares of S-8 registered free-trading common stock ~~under~~to ~~Scientific~~a ~~Advisory~~consultant ~~Board Agreement of the 2016 Equity Plan~~ with a fair market value of $~~151~~700,000 for legal and general consulting services under a consulting agreement dated January 13, 2017.

On ~~March~~ 22February 16, ~~2016~~2017, the Company issued 5 10,000,000 shares of S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.0105 and a fair market value of $75700,~~500~~000 to a consultant under a consulting agreement dated January 13, 2017.

On ~~May~~ 10February 28, ~~2016~~2017, the Company issued 18 10,000,000 shares of S-8 registered free-trading common stock ~~for balance of shares exercised~~ under an Option Agreement ~~dated~~of ~~February 22,~~ 2016 ~~under 2016~~ Equity Award Plan B with exercise price at $0.0104 and a fair market value of $~~221~~815,~~400~~000 to aAlfredo ~~consultant~~Dupetit-Bernardi, ~~under~~President/CEO ~~management~~of ~~agreement~~Cannabis ~~for~~Science aEurope ~~total~~GmbH ~~Stock~~under an Option ofAgreement ~~25,000,000~~dated ~~common~~January ~~shares with fair market value of $307~~24,~~500~~ 2017.

On ~~May~~ 10March 2, ~~2016~~2017, the Company issued 183,~~500~~000,000 shares of R144 ~~S-8~~restricted ~~registered free-trading~~ common stock ~~for~~to ~~balance~~a ofconsultant ~~shares exercised under an Option Agreement dated February 22, 2016 under 2016 Equity Award Plan~~ with ~~exercise price at $0.01 and~~ a fair market value of $~~227~~238,~~550~~500 tofor aconsulting ~~consultant~~services under ~~management agreement for~~ a ~~total~~consulting ~~Stock Option of 25,000,000 common shares with fair market~~agreement ~~value~~dated ofMarch ~~$307~~2,~~500~~ 2017.

On ~~May~~ 16March 7, ~~2016~~2017, the Company issued 515,000,000 shares ~~R144 restricted common stock and 2,500,000 shares of~~ S-8 registered free- trading common stock under ~~an Application Development and Consulting Management Agreement of~~ the ~~2015~~2016 Equity Award Plan B with a fair market value of $861,~~250~~270,500 for consulting services under a consulting agreement dated March 7, 2017.

On ~~May~~ 16March 13, ~~2016~~2017, the Company issued 10,000,000 shares ~~R144~~S-8 registered ~~restricted~~free trading common stock under anthe ~~International~~2016 ~~Government~~Equity ~~Affairs~~Award ~~Board Member~~Plan ~~Agreement~~B with a fair market value of $~~151~~883,000 for consulting services under a consulting agreement dated July 6 2016.

On ~~May~~ 16March 13, ~~2016~~2017, the Company issued 515,000,000 shares of S-8 registered free- trading common stock under ~~Option~~the ~~Agreement of~~ 2016 Equity Award Plan B with ~~exercise price at $0.01 and~~ a fair market value of $751,324,500 tofor aconsulting ~~consultant~~ services under ~~management~~a consulting agreement dated April 29, 2015.

On ~~May~~ 16March 27, ~~2016~~2017, the Company issued 1015,000,00000 shares of S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.01075 and a fair market value of $~~151~~1,140,000 to ~~Alfredo~~a ~~Bernardi~~consultant ~~Dupetit,~~under ~~President~~an &Option ~~CEO~~Agreement ~~of Cannabis~~dated ~~Science~~March ~~Europe~~27, ~~GmbH~~2017.

10ITEM 4. DEFAULTS UPON SENIOR SECURITIES

~~On May 16, 2016, the Company issued 15,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at $0~~None.~~01 and a fair market value of $264,000 to a consultant under management agreement.~~

~~On May~~ITEM ~~16, 2016, the Company issued 10,000,000 shares of S-8 registered free-trading common stock under Option Agreement of 2016 Equity Award Plan with exercise price at $0~~5.01 ~~and~~MINE aSAFETY ~~fair market value of $176,000 to a consultant under management agreement.~~DISCLOSURES

On July 26, 2016, the Company issued 7,500,000 shares of S-8 registered free-trading common stock to a consultant with a fair market value of $90,000 for bonus and services under October 21, 2015 agreement.N/A

~~On July~~ITEM ~~26,~~6. ~~2016,~~OTHER ~~the Company issued 5,000,000 shares of S-8 registered free-trading common stock to a consultant with a fair market value of $60,000 for bonus and services under March 16, 2015 agreement.~~INFORMATION

~~On July~~See ~~26,~~Financial ~~2016,~~Statement ~~the~~Notes ~~Company~~4 ~~issued~~in ~~5,000,000~~regards ~~shares~~to ~~of S-8 registered free-trading common~~ stock ~~to a consultant with a fair market~~compensation ~~value of $60,000~~ for ~~bonus~~officers and ~~services under September 18, 2015 agreement~~directors.

On July 26, 2016, the Company issued 5,000,000 shares of S-8 registered free-trading common stock to a consultant with a fair market value of $60,000 for bonus and services under July 6, 2016 International Property Development Consulting Agreement.14

~~On July~~ITEM 26, 2016, the Company issued 2,500,000 shares of S-8 registered free-trading common stock to Robert Kane, COO/director of the Company with a fair market value of $30,000 for Management Fees under January 20, 2015 Executive Management Agreement7. EXHIBITS

On August 3, 2016, the Company issued 2,500,000 shares of S-8 registered free-trading common stock to a consultant with a fair market value of $38,500 for services under August 3, 2016 Consulting Agreement.

Exhibit No.	Document Description	Filed Herewith (X) Incorporated by ref (I)

31.1	Certification by Raymond C. Dabney, Chief Executive Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
31.2	Certification by Benjamin Tam, Chief Financial Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
32.1	Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
32.2	Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
99.1	Promissory Notes	X
EX-101.INS	XBRL Instance Document	X
EX-101.SCH	XBRL Taxonomy Extension Schema	X
EX-101.CAL	XBRL Taxonomy Extension Calculation Linkbase	X
EX-101.LAB	XBRL Taxonomy Extension Label Linkbase	X
EX-101.PRE	XBRL Taxonomy Extension Presentation Linkbase	X
EX-101.DEF	XBRL Taxonomy Extension Definition Linkbase	X

On August 3, 2016, the Company issued 7,500,000 shares of S-8 registered free-trading common stock to a legal advisor as retainer with a fair market value of $90,000 for legal services under July 22, 2016 Consulting Agreement.15

On August 10, 2016, the Company entered into a partial debt settlement agreement with Raymond C. Dabney, CEO/Director of the Company, to retire $250,000 of the $975,407.39 in promissory notes originated on August 9, 2016 as result of unpaid management fees and bonuses from February 9, 2012 to June 30, 2016 with no interest, and issued 250,000,000 Rule 144 restricted common shares of the Company at a deemed price of $0.001 per share as partial payment of the promissory note to settle the debt for a loss on settlement of $3,550,000.SIGNATURES

~~On July~~Pursuant ~~26,~~to ~~2016,~~ the ~~Company~~requirements ~~issued 5,000,000 shares~~ of ~~S-8~~the ~~registered~~Securities ~~free-trading~~Exchange ~~common stock under Option Agreement~~ Act of ~~2016 Equity~~1934, ~~Award~~the ~~Plan~~registrant ~~with~~has ~~exercise~~duly ~~price~~caused atthis ~~$0.01~~report ~~and~~to abe ~~fair~~signed ~~market~~on ~~value~~its ofbehalf ~~$76,500~~by tothe aundersigned ~~consultant~~thereunto ~~under~~duly ~~July 4, 2016 management agreement~~authorized.

On September 14, 2016, the Company issued 5,000,000 shares of R144 restricted common stock to Benjamin Tam, CFO/Secretary/Director of the Company with a fair market value of $70,000 for services under September 14, 2016 Executive Management Agreement.


	CANNABIS SCIENCE INC.


Date: August 10, 2017	/s/ Raymond C. Dabney
		Raymond C. Dabney
		Chief Executive Officer


Date: August 10, 2017	/s/ Benjamin Tam
		Benjamin Tam
		Chief Financial Officer

On September 27, 2016, the Company entered an Option Agreement with a consultant under 2016 Equity Award Plan B at exercise price of $0.01 to issue 15,000,000 shares of S-8 registered free-trading common stock with a fair market value of $214,500. The shares were exercised on September 27, 2016 and issued on October 7, 2016.

On September 27, 2016, the Company entered an Option Agreement with a consultant for International Property Development under 2016 Equity Award Plan B at exercise price of $0.01 to issue 10,000,000 shares of S-8 registered free-trading common stock with a fair market value of $143,000. The shares were exercised on September 27, 2016 and issued on October 25, 2016.

On September 27, 2016, the Company entered an Option Agreement with a consultant for International Government Affairs under 2016 Equity Award Plan B at exercise price of $0.01 to issue 5,000,000 shares of S-8 registered free-trading common stock with a fair market value of $71,500. The shares were exercised on September 27, 2016 and have not been issued.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

N/A

ITEM 5. OTHER INFORMATION

See Financial Statement Notes 4 in regards to stock compensation for officers and directors.

ITEM 6. EXHIBITS

Exhibit No.	Document Description	Filed Herewith (X) Incorporated by ref (I)
31.1	Certification by Raymond C. Dabney, Chief Executive Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
31.2	Certification by Benjamin Tam, Chief Financial Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
32.1	Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
32.2	Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
EX-101.INS	XBRL Instance Document	X
EX-101.SCH	XBRL Taxonomy Extension Schema	X
EX-101.CAL	XBRL Taxonomy Extension Calculation Linkbase	X
EX-101.LAB	XBRL Taxonomy Extension Label Linkbase	X
EX-101.PRE	XBRL Taxonomy Extension Presentation Linkbase	X
EX-101.DEF	XBRL Taxonomy Extension Definition Linkbase	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CANNABIS SCIENCE INC.
Date: November 14, 2016	/s/ Raymond C. Dabney
		Raymond C. Dabney
		Chief Executive Officer
Date: November 14, 2016	/s/ Benjamin Tam
		Benjamin Tam
		Chief Financial Officer

Filing Compare · CANNABIS SCIENCE, INC.